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economic burdens of this category of mental illnesses have not been well studied yet. The objective of
this study was to estimate the societal cost of anxiety disorders for the ambulatory adult population of
the U.S.
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years and older, who reported a diagnosis of, or had a medical event associated with anxiety disorder(s),
were classified as anxiety population. Number of suicides due to anxiety disorders was estimated using
the NVSS data. Direct medical costs attributable to anxiety disorders were estimated as the expenditures
incurred by anxiety patients in excess of those incurred by anxiety-free population. Several multivariate
regression analyses, using generalized linear models, were conducted to calculate the overall incremental
direct medical costs associated with anxiety disorders, as well as cost by healthcare delivery setting, and
cost for different sub-populations. Indirect costs were estimated using the Human Capital Approach
(HCA). Morbidity cost was estimated by valuing the time period in which individuals had to stay in bed
due to anxiety disorders. Mortality cost was estimated as the productivity loss from age at death to life
expectancy.
Results: Among adult participants in 2009-2010 MEPS, 30.35 million (8.74%) reported being diagnosed
with anxiety disorder(s). It was also estimated that in 2010, 3,497 suicides were due to anxiety disorders.
The annual overall direct medical costs associated with anxiety disorders was estimated at $1657.52 per
person (SE: $238.83; p <0.001), or $33.71 billion in total. Inpatient visits, prescription medications, and
office-based visits together accounted for almost 93% of the overall cost. The increase in direct medical
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increase in medical expenditure. Regarding aspects of indirect cost, morbidity and mortality cost were
estimated at $12.72 billion and $2.34 billion in 2013 US dollars, respectively. The 2013 societal cost of
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ABSTRACT
Background: Anxiety disorders are the most common psychiatric illness in the
United States. However, economic burdens of this category of mental illnesses have not
been well studied yet. The objective of this study was to estimate the societal cost of
anxiety disorders for the ambulatory adult population of the U.S.
Data and Method: Data was collected from the 2009 and 2010 Medical
Expenditure Panel Survey (MEPS), Bureau of Labor Statistics (BLS), and National Vital
Statistics System (NVSS). Cost components included in the analyses were direct medical
costs (i.e. cost for inpatient visits, outpatient visits, emergency room visits, office-based
visits, prescription medications, and other services), and indirect cost (i.e. morbidity and
mortality costs). Anxiety patients were identified using MEPS data. More specifically,
individuals 18 years and older, who reported a diagnosis of, or had a medical event
associated with anxiety disorder(s), were classified as anxiety population. Number of
suicides due to anxiety disorders was estimated using the NVSS data. Direct medical
costs attributable to anxiety disorders were estimated as the expenditures incurred by
anxiety patients in excess of those incurred by anxiety-free population. Several
multivariate regression analyses, using generalized linear models, were conducted to
calculate the overall incremental direct medical costs associated with anxiety disorders,
as well as cost by healthcare delivery setting, and cost for different sub-populations.
Indirect costs were estimated using the Human Capital Approach (HCA). Morbidity cost
was estimated by valuing the time period in which individuals had to stay in bed due to
anxiety disorders. Mortality cost was estimated as the productivity loss from age at death
to life expectancy.
Results: Among adult participants in 2009-2010 MEPS, 30.35 million (8.74%)
reported being diagnosed with anxiety disorder(s). It was also estimated that in 2010,
3,497 suicides were due to anxiety disorders. The annual overall direct medical costs
associated with anxiety disorders was estimated at $1657.52 per person (SE: $238.83; p
<0.001), or $33.71 billion in total. Inpatient visits, prescription medications, and officebased visits together accounted for almost 93% of the overall cost. The increase in direct
medical cost due to anxiety disorders was higher among White non-Hispanics ($1879.31)
than Black non-Hispanics ($1459.30). For non-Hispanics, anxiety was not associated
with a statistically significant increase in medical expenditure. Regarding aspects of
indirect cost, morbidity and mortality cost were estimated at $12.72 billion and $2.34
billion in 2013 US dollars, respectively. The 2013 societal cost of anxiety disorders was
estimated at $48.72 billion.
Conclusion: The current study demonstrates conclusively that anxiety disorders,
with the annual cost of $48.72 billion in 2013 US dollars, absorb a significant portion of
US healthcare resources and should be prioritized by policymakers and healthcare
providers who aim to reduce downstream costs of mental disorders.
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CHAPTER 1.

INTRODUCTION

Data on the economic burden of anxiety disorders are limited. But this category of
mental illnesses is known to be the most prevalent, and one of the most expensive
psychiatric disorders in the U.S. The current study intends to answer the following
research question: What are the economic burdens of anxiety disorders to the ambulatory
adult population of the U.S.?
The following sections describe the importance of conducting a cost of illness
study for anxiety disorders, the existing gap in the relevant literature, the potential
contributions of this research to the current literature, and detailed explanation of specific
aims of the study.
Importance of Conducting a Cost of Illness Study for Anxiety Disorders
Why a Cost of Illness Analysis?
According to Centers for Medicare & Medicaid Services (CMS) “U.S. health care
spending reached $2.7 trillion in 2011, or $8,680 per person.”1(p. 2) There has been a
growing rate of 3.9 percent in health spending since 2009. Also from 2009 to 2011,
health spending was 17.9 percent of Gross Domestic Product (GDP). In comparison with
other countries in the Organization for Economic Cooperation and Development
(OECD), the United States has the highest health spending in terms of share of GDP. In
fact, “Americans spent more than twice as much as relatively rich European countries
such as France, Sweden and the United Kingdom.”2(p. 1) CMS has projected for this share
to rise to 20 percent of GDP by 2020.
There is no simple and straightforward solution for controlling this high and everincreasing rate of spending on healthcare in the United States; but, identifying the most
expensive medical conditions and trying to alleviate their economic burden, through
disease management interventions, is definitely a required step to be undertaken in this
way. According to Joel & Segel, “Cost-of-illness studies measure the economic burden of
a disease or diseases and estimate the maximum amount that could potentially be saved
or gained if a disease were to be eradicated.”3(p. 2) In developing cost-containment policies
and interventions, cost of illness (COI) analysis enables policymakers to identify diseases
which need to be addressed with the highest priority.
No one can argue that healthcare resources, like many other forms of resource, are
scarce; and the more resources absorbed by heath sector, the less will be left for other
sectors such as education, defense, etc. A cost of illness study is not enough to set
priorities for the objective of resource allocation (for that purpose, one needs
effectiveness data as well as cost data). However, it is a main component of any costeffectiveness or cost-utility analysis. Nowadays, cost of illness studies are being widely
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used by health economists, pharmaceutical companies, clinicians, and policymakers to set
research agendas and allocate resources.4,5
Why Examining Costs by Service Category and for Different Sub-populations?
Even though cost of illness analysis is a crucial primary step in identifying costly
medical conditions, further information is needed if effectively reducing the burden of
these conditions is desired. To reduce the burden of illness, just knowing the dollar
amount in terms of cost of illness is not enough. In fact, one also needs to know the
distribution of costs among different health sectors (inpatient, outpatient, emergency
room, prescription medication …) and subpopulations (based on gender, race, age …) to
find out if resources are being distributed disproportionally. Knowing which
subpopulations or health sectors incur higher costs, policymakers can come up with
tailored disease management interventions to address high costs specifically in those subpopulations/health sectors.
Healthcare costs are not distributed proportionally among different subpopulations. According to the Medical Expenditure Panel Survey (MEPS), in 2010,
individuals with some college degree had the highest total healthcare expenditure in
comparison with those in other educational levels. The same can be said for Whites,
females, and married individuals. So having the estimation of cost of illness for the whole
population (who suffer from that disease), one also needs to know how this burden is
distributed among different groups of people. In the same manner, distribution of cost
among different service categories will yield useful information as to which category of
health services may benefit the most from disease management programs.
Why Anxiety Disorders?
Costly medical conditions can be amongst the underlying causes of skyrocketing
healthcare expenditures in the U.S. In this regard, it is good to know that one group of
these expensive medical conditions are anxiety disorders. Anxiety is a natural response
and a necessary warning adaptation in humans. Everybody has experienced anxiety in the
form of increased heart rate and tensed muscles. However, anxiety can become a
pathologic disorder when it is excessive and uncontrollable; In other words, when it
occurs without any recognizable reason or when the reason does not warrant such a
reaction. If no medical condition accounts for symptoms, they are attributed to anxiety
disorders.6
According to the Diagnostic and Statistical Manual of Mental Disorders, fourth
edition, text revision (DSM IV-TR),7 anxiety disorders categorize a large number of
disorders including acute stress disorder, post-traumatic stress disorder (PTSD), phobias
(including social phobia), agoraphobia (with or without a history of panic disorder), panic
disorder (with or without agoraphobia), generalized anxiety disorder (GAD), obsessivecompulsive disorder (OCD), and anxiety disorders due to known physical causes (these
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include general medical conditions or substance abuse). The primary feature of these
disorders is abnormal or inappropriate anxiety. These disorders usually interfere with a
patient’s work, schooling, and family life so that in severe cases, they can adversely
affect their function. For instance, anxiety disorders can be an underlying cause of
alcohol and substance abuse.
Fortunately, anxiety disorders are highly treatable, and most people with these
conditions can have fulfilling lives if they receive appropriate treatment. In general,
anxiety disorders are treated with medication, specific types of psychotherapy, or both.
“Treatment choices depend on the problem and the person’s preference. Before treatment
begins, a doctor must conduct a careful diagnostic evaluation to determine whether a
person’s symptoms are caused by an anxiety disorder or a physical problem.”8(p. 14)
Each year, almost one out of three Americans age 18 years or older (12-month
prevalence=26.2%), will experience at least one form of mental disorders (i.e. anxiety
disorders, mood disorders, impulse-control disorders, and substance use disorders).9 More
than two thirds of these individuals (12-month prevalence=18.1%) suffer from one (or
more) form of anxiety disorders (alone or along with another mental condition).9 In other
words, anxiety disorders represent the most common psychiatric illnesses in the U.S. The
annual societal cost of anxiety disorders in the U.S. in 1990 was estimated to range from
US$42 to US$47 billion, nearly approaching the estimates of the cost of depression (from
US$44 to US$53 billion) for the same time frame.5,10 With respect to the high prevalence
of anxiety disorders in the U.S. and evidence from previous research,5,10 it is expected
that this category of mental illnesses imposes a significant economic burden to society. In
this regard, a more current and comprehensive evaluation of healthcare expenditures
attributable to anxiety disorders is warranted. Such evaluation may guide clinicians and
policymakers in developing and improving disease management programs, and provide a
basis for conducting cost-effectiveness analysis of new treatment interventions.
The Existing Gap in the Literature
In order to have a reliable estimation of the economic burden of a disease to
society, there are several factors that must be taken into account:
x

Both direct and indirect costs should be included in the analysis.

x

The sample should be representative of the entire population in which results are
to be generalized to.

x

If there is more than one diagnosis for a condition, all possible diagnoses should
be considered.

x

In estimating the costs, not only the costs directly due to the condition of interest
should be included, but also costs due to the comorbidities and complications
resulted from that condition should be considered.
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x

When using different data sources, the potential inconsistency between these data
sources should be taken into account.

An overview of the literature on cost of illness studies for anxiety disorders
reveals that there are a limited number of studies in this field. In fact, the only studies that
estimated direct and indirect costs of anxiety disorders from a societal perspective in the
U.S. were conducted far back, in 1996 and 1999 by DuPont et al.5 and Greenberg et al.10
DuPont et al.5 conducted a cost of illness analysis from a societal perspective, by
including direct medical costs, direct non-medical costs, and indirect costs (morbidity and
mortality costs). The major limitation of their study is that in estimating the cost of illness
for anxiety disorders, they only considered the costs that were incurred directly due to
anxiety disorders; but they did not account for the increase in general use of medical
services in patients suffering from anxiety disorders. In addition, they did not include all
diagnoses of anxiety disorders in their analysis (data on costs due to PTSD and acute
stress disorder were not collected). All of this might have led to an underestimation of the
true burden of anxiety disorders. Another limitation of the study is related to the data
collection process. Data on utilization and cost was collected from several different data
sources. For instance, they used more than six databases (such as National Hospital
Discharge Survey, National Nursing Home Survey, Pharmaceutical Data Source …) for
calculating direct medical costs. The potential inconsistencies between different data
sources may later cast doubt on the reliability of results.
Greenberg et al.10 reduced the inconsistency in data by using less data sources.
They collected the majority of data from the National Comorbidity Survey. The cost
components included in their study were direct psychiatric costs, direct non-psychiatric
costs, and indirect costs (morbidity and mortality costs). Direct non-psychiatric costs
accounted for most of the cost of illness for anxiety disorders. However, estimation of
this cost component (which accounted for more than half of their estimated cost of
illness) was based on results from a single staff–model HMO that may not be fully
generalizable to the entire population. So, their estimation of cost of illness for anxiety
disorders may not be representative of the true burden of this condition to the whole
society. In addition, they did not include all diagnoses of anxiety disorders in their
analysis (data on costs due to OCD and acute stress disorder were not collected).
In more recent studies, the study population is either not from the U.S. or not
representative of the whole U.S. population,11-15 the perspective is not societal,11,16-22 both
direct and indirect costs are not estimated,11,15-23 or not all anxiety diagnoses are included
in the study.16,17,24-29
Potential Contributions of This Research to the Current Literature
Due to the high prevalence of anxiety disorders in the U.S. and the evidence from
previous research on anxiety-related costs,5,10 it is expected that this category of mental
illnesses imposes a significant economic burden to society. Considering the fact that
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costly medical conditions have been always a high priority to policymakers in their effort
to reduce healthcare costs, a well-conducted cost of illness for anxiety disorders can
provide them with a reliable estimation of the economic burden of these conditions.
Moreover, identifying the distribution of costs among different sub-populations and
health sectors may enable them to come up with tailored disease management programs
to reduce the costs.
The specific features of the study which distinguish it from the previous works,
and also add to the current knowledge are as follows:
x

Results of this research will provide the most comprehensive and updated
estimate of cost of illness for anxiety disorders, for the ambulatory adult
population of the U.S.

x

It is the first study that measures costs at the population level, as well as for
different sub-populations.

x

The sample is representative of the whole U.S civilian non-institutionalized
population 18 years of age and older. So, results can be generalized to this group
of individuals (Civilian-non-institutionalized population refers to communitydwelling population or ambulatory population. individuals in the military and
those residing in nursing homes, assisted living facilities, and prisons are not
included in the civilian-non-institutionalized population. Throughout this
research, civilian non-institutionalized population and ambulatory population
phrases are used alternatively).

x

The societal perspective enables the researcher to measure the economic burdens
of anxiety disorders to the whole society regardless of who incurred the costs.

x

Instead of getting data from several different data sources, which may lead to
inconsistency in data and later affect the reliability of results, only one database
will be used to collect data on healthcare utilization and costs.

x

All possible diagnoses of anxiety disorders will be included in the analysis.

x

The estimation of cost of illness will not only capture the costs directly due to
anxiety disorders, but it will also include cost of their comorbidities and
complications.

x

The analysis technique used will control for all factors that may affect healthcare
expenditures, therefore, researchers can estimate costs solely due to anxiety
disorders.
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Specific Aims
Specific aims of the study are presented in this section. For all specific aims,
estimates will be provided for the ambulatory adult (18 years and older) population of the
U.S.
x

Specific Aim 1 (SA1): To estimate direct medical cost and indirect costs
(morbidity cost, mortality cost) of anxiety disorders.

x

Specific Aim 2 (SA2): To estimate direct medical costs attributable to anxiety
disorders by major service categories (i.e. inpatient visits, outpatient visits, officebased medical visits, emergency room visits, prescription medications, and other
services).

x

Specific Aim 3 (SA3): To estimate direct medical costs attributable to anxiety
disorders for different sub-populations (based on gender, race/ethnicity, age,
marital status, poverty category, education, geographic region, Metropolitan
Statistical Area (MSA), and insurance coverage).
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CHAPTER 2.

LITERATURE REVIEW

The goal of this chapter is to provide a review of literature relevant to the purpose
of this research. It has two main sections. The first section provides an introduction to
anxiety disorders, their epidemiology and treatments. The second section is devoted to
cost of illness studies. It starts with description and history of cost of illness studies and
continues with reviewing the cost of illness studies for anxiety disorders. In order to find
these studies, we conducted a search in Pubmed, Ovid, PsycINFO, and Google Scholar
for articles published after 1990. The search words were cost, expenditure, cost of illness,
burden, and anxiety disorders.
An Overview of Anxiety Disorders
Description of Anxiety Disorders
According to the American Psychiatric Association,7 anxiety disorders categorize
a large number of disorders including acute stress disorder, agoraphobia (with or without
a history of panic disorder), generalized anxiety disorder (GAD), obsessive-compulsive
disorder (OCD), panic disorder (with or without Agoraphobia), phobias (including social
phobia), and post-traumatic stress disorder (PTSD). The primary feature of these
disorders is abnormal or inappropriate anxiety. Everybody has experienced anxiety in
forms of increased heart rate and tensed muscles. But anxiety becomes a problem when it
occurs without any recognizable reason, or when the reason does not warrant such a
reaction. If no medical condition accounts for symptoms, they are attributed to anxiety
disorders.6
The following sections provide information on etiology, symptoms and prognosis
of different diagnoses of anxiety disorders, quoted from AllPsych Online
(http://allpsych.com/disorders/anxiety/index.html).6
Acute Stress Disorder
x

Etiology: “By definition, acute stress disorder is a result of a traumatic event in
which the person experienced or witnessed an event that involved threatened or
actual serious injury or death and responded with intense fear and helplessness.”6

x

Symptoms: “Symptoms include dissociative symptoms such as numbing,
detachment, a reduction in awareness of the surroundings, derealization, or
depersonalization; re-experiencing of the trauma, avoidance of associated stimuli,
and significant anxiety, including irritability, poor concentration, difficulty
sleeping, and restlessness. The symptoms must be present for a minimum of two
days and a maximum of four weeks and must occur within four weeks of the
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traumatic event for a diagnosis to be made.”6
x

Prognosis: “Prognosis for this disorder is very good. If it should progress into
another disorder, success rates can vary according to the specific of that
disorder.”6

Agoraphobia (with or without a History of Panic Disorder)
x

Etiology: “Agoraphobia can develop out of simple phobias or it can be a result of
extreme trauma, although it is often a result of numerous panic attacks such as
those found in panic disorder.”6

x

Symptoms: “Agoraphobia, like other phobias, is made up of extreme anxiety and
fear. Different from other phobias, however, is the generalization which occurs.
Agoraphobia is the anxiety about being in places where escape might be difficult
or embarrassing or in which help may not be available should a panic attack
develop. It can be sub diagnosed as either ‘with’ or ‘without’ panic disorder.
Typically situations that invoke anxiety are avoided and in extreme cases, the
person may never or rarely leave their home.”6

x

Prognosis: “Prognosis is good, especially if the individual has some insight into
the development of the disorder and if their fears are irrational and there is insight
into this.”6

Generalized Anxiety Disorder (GAD)
x

Etiology: “Often anxiety gets generalized to other situations, and can then become
overwhelming or associated with life in general. Typically GAD develops over a
period of time and may not be noticed until it is significant enough to cause
problems with functioning.”6

x

Symptoms: “As its name implies, GAD is evidenced by general feelings of
anxiety such as mild heart palpitations, dizziness, and excessive worry. The
symptoms are difficult to control for the individual and are not related to a
specific event (such as in PTSD) and are not as severe as those found with Panic
Disorder.”6

x

Prognosis: “Prognosis is good for the more extreme symptoms, but those
associated with underlying fears are more difficult to treat (such as excessive
worry). Working through childhood issues can be helpful as these tend to get
distorted as they follow us into adulthood (e.g., over-controlling parental styles,
sexual abuse, and childhood phobias).”6
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Obsessive-compulsive Disorder (OCD)
x

Etiology: “Both biological and psychological causes have been found in OCD.”6

x

Symptoms: “The key features of this disorder include obsessions (persistent, often
irrational, and seemingly uncontrollable thoughts) and compulsions (actions
which are used to neutralize the obsessions). A good example of this would be an
individual who has thoughts that he is dirty, infected, or otherwise unclean which
are persistent and uncontrollable. In order to feel better, he washes his hands
numerous times throughout the day, gaining temporary relief from the thoughts
each time. For these behaviors to constitute OCD, it must be disruptive to
everyday functioning (such as compulsive checking before leaving the house
making you extremely late for all or most appointments, washing to the point of
excessive irritation of your skin, or inability to perform everyday functions like
work or school because of the obsessions or compulsions).”6

x

Prognosis: “Prognosis for this disorder has a wide range, depending upon how the
individual responds to medication and how deep rooted the underlying issues
are.”6

Panic Disorder (with or without Agoraphobia)
x

Etiology: “Often the symptoms of this disorder come on rapidly and without an
identifiable stressor. The individual may have had periods of high anxiety in the
past, or may have been involved in a recent stressful situation. The underlying
causes, however, are typically subtle.”6

x

Symptoms: “Panic Disorder is characterized by sudden attacks of intense fear or
anxiety, usually associated with numerous physical symptoms such as heart
palpitations, rapid breathing or shortness of breath, blurred vision, dizziness, and
racing thoughts. Often these symptoms are thought to be a heart attack by the
individual, and many cases are diagnosed in hospital emergency rooms.”6

x

Prognosis: “Prognosis for this disorder is very good if the above conditions are
met. Left untreated, however, symptoms can worsen and Agoraphobia can
develop. In these cases, the individual has developed such an intense fear that
leaving the safety of home feels impossible.”6

Phobias (Including Social Phobia)
x

Etiology: “Often a traumatic event is the precursor for a phobia, which may or
may not be at the conscious level.”6

x

Symptoms: “Symptoms include either extreme anxiety and fear associated with
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the object or situation or avoidance. To be diagnosed, the symptoms must be
disruptive to everyday functioning (such as quitting a great job merely because
you have to use an elevator).”6
x

Prognosis: “Prognosis is very good if treated effectively.”6

Post-traumatic Stress Disorder (PTSD)
x

Etiology: “By definition, PTSD always follows a traumatic event which causes
intense fear and/or helplessness in an individual. Typically the symptoms develop
shortly after the event, but may take years. The duration for symptoms is at least
one month for this diagnosis.”6

x

Symptoms: “Symptoms include re-experiencing the trauma through nightmares,
obsessive thoughts, and flashbacks (feeling as if you are actually in the traumatic
situation again). There is an avoidance component as well, where the individual
avoids situations, people, and/or objects which remind him or her about the
traumatic event (e.g., a person experiencing PTSD after a serious car accident
might avoid driving or being a passenger in a car). Finally, there is increased
anxiety in general, possibly with a heightened startle response (e.g., very jumpy,
startle easy by noises).”6

x

Prognosis: “Prognosis ranges from moderate to very good. Those with the best
prognosis include situations where the traumatic event was acute or occurred only
one time (e.g., car accident) rather than chronic or on-going trauma (e.g., ongoing
sexual abuse, war).”6
Epidemiology of Anxiety Disorders

For any anxiety disorder, 12-month prevalence is 18.1% of the U.S. adult
population.9 Lifetime prevalence is 28.8% of the U.S. adult population and 25.1% of
children and adolescents.30 Women are 60% more likely than men to experience an
anxiety disorder over their lifetime. Non-Hispanic Blacks are 20% less likely, and
Hispanics are 30% less likely, than non-Hispanic Whites to experience an anxiety
disorder during their lifetime. Individuals in the age group of 30-44 have the highest risk
of developing an anxiety disorder over their lifetime (35.1%), while those who are 60 or
older have the lowest risk (15.3%).30 Table 2-1 shows the epidemiology of anxiety
disorders in the U.S. adult population for each specific diagnosis.
Treatment of Anxiety Disorders
According to the National Institute of Mental Health (NIMH) “anxiety disorders
are treated with medication, specific types of psychotherapy, or both. Treatment choices
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Table 2-1.

Prevalence of anxiety disorders for the U.S. adult population.

Diagnosis
Any Anxiety Disorder
Acute Stress Disorder
Agoraphobia
Generalized Anxiety Disorder
Social Phobias
Specific Phobias
Post-traumatic Stress Disorder
Obsessive-compulsive Disorder
Panic Disorder

Lifetime prevalence
28.8%
7.8%
1.4%
5.7%
12.1%
12.5%
6.8%
1.6%
4.7%

12-month prevalence
18.1%
0.8%
3.1%
6.8%
8.7%
3.5%
1.0%
2.7%

Source: Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence,
severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity
Survey Replication. Arch Gen Psychiatry. Jun 2005;62(6):617-627; Kessler RC,
Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age
of-onset distributions of DSM-IV disorders in the National Comorbidity Survey
Replication. Arch Gen Psychiatry. Jun 2005;62(6):593-602.
depend on the problem and the person’s preference. Before treatment begins, a doctor
must conduct a careful diagnostic evaluation to determine whether a person’s symptoms
are caused by an anxiety disorder or a physical problem.”8(p. 14)
The following sections, quoted from the Booklet of Anxiety Disorders,8 describe
treatment options for anxiety disorders.
Medication
“Medication will not cure anxiety disorders, but it can keep them under control
while the person receives psychotherapy.”8(p. 14) Antidepressants, anti-anxiety drugs, and
betablockers are the three major categories medications used for anxiety disorders.
Antidepressants. Even though Antidepressants were originally developed to treat
depression, they are also effective in treating anxiety disorders.8 The specific
antidepressant used to treat anxiety disorders are listed below:
x

Selective serotonin reuptake inhibitors (SSRIs): “SSRIs alter the levels of the
neurotransmitter serotonin in the brain, which, like other neurotransmitters, helps
brain cells communicate with one another. Fluoxetine (Prozac®), sertraline
(Zoloft®), escitalopram (Lexapro®), paroxetine (Paxil®), and citalopram
(Celexa®) are some of the SSRIs commonly prescribed for panic disorder, OCD,
PTSD, and social phobia. SSRIs are also used to treat panic disorder when it
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occurs in combination with OCD, social phobia, or depression. Venlafaxine
(Effexor®), a drug closely related to the SSRIs, is used to treat GAD. These
medications are started at low doses and gradually increased until they have a
beneficial effect. SSRIs have fewer side effects than older antidepressants. Their
common side effects are slight nausea or jitters (when people first start to take
them) as well as sexual dysfunction.”8(p. 15)
x

Tricyclics: “Tricyclics are older than SSRIs and work as well as SSRIs for anxiety
disorders other than OCD. Tricyclics include imipramine (Tofranil®), which is
prescribed for panic disorder and GAD, and clomipramine (Anafranil®), which is
the only tricyclic antidepressant useful for treating OCD. They are also started at
low doses that are gradually increased. They sometimes cause dizziness,
drowsiness, dry mouth, and weight gain.”8(p. 15)

x

MAOIs: “Monoamine oxidase inhibitors (MAOIs) are the oldest class of
antidepressant medications. The MAOIs most commonly prescribed for anxiety
disorders are phenelzine (Nardil®), followed by tranylcypromine (Parnate®), and
isocarboxazid (Marplan®),which are useful in treating panic disorder and social
phobia. If taken with food and beverages containing tyramine or certain
medications, including some types of birth control pills, pain relievers, cold and
allergy medications, and herbal supplements drug interaction will occur which
leads to increase in blood pressure.”8(p. 16)

Anti-anxiety drugs. “High potency benzodiazepines combat anxiety and its main
side effect is that patient may get dependent to it. Clonazepam (Klonopin®) is used for
social phobia and GAD, lorazepam (Ativan®) is helpful for panic disorder, and
alprazolam (Xanax®) is useful for both panic disorder and GAD. This drug in now less
prescribed due to its side effects.”8(p. 16)
Betablockers. “Betablockers such as propranolol (Inderal®), which is used to
treat heart conditions, can prevent the physical symptoms that accompany certain anxiety
disorders, particularly social phobia.”8(p. 17)
Psychotherapy
“Psychotherapy involves talking with a trained mental health professional, such as
a psychiatrist, psychologist, social worker, or counselor, to discover what caused an
anxiety disorder and how to deal with its symptoms.”8(p. 17) One of the specific forms of
psychotherapy, which is very effective in treating some forms of anxiety disorders, is
called Cognitive Behavioral Therapy (CBT). According to the booklet of NIMH on
anxiety disorders:
CBT is very useful in treating anxiety disorders. The cognitive part helps people
change the thinking patterns that support their fears, and the behavioral part helps
people change the way they react to anxiety-provoking situations. There is some
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evidence that the benefits of CBT last longer than those of medication for people
with panic disorder, and the same may be true for OCD, PTSD, and social phobia.
If a disorder recurs at a later date, the same therapy can be used to treat it
successfully a second time. Medication can be combined with psychotherapy for
specific anxiety disorders, and this is the best treatment approach for many
people.8(p. 17)
Diagnosis Specific Treatment
The following sections, quoted from AllPsych Online
(http://allpsych.com/disorders/anxiety/index.html),6 provide treatment recommendations
for each specific diagnosis of anxiety disorder.
x

Acute Stress Disorder: “The disorder may resolve itself with time or may develop
into a more severe disorder such as PTSD. Medication can be used for a very
short duration (up to four weeks) or psychotherapy can be utilized to assist the
victim in dealing with the fear and sense of helplessness.”6

x

Agoraphobia: “(with or without a history of panic disorder): Treatment may
involve anxiety reduction techniques aimed at increasing the control a person
feels over his or her anxiety and fears. Other approaches require the individual to
work through their anxiety in relation to interpersonal or childhood issues.”6

x

Generalized Anxiety Disorder (GAD): “Medication and/or psychotherapy have
been found to be helpful, especially therapy aimed at teaching the client how to
gain control over the symptoms.”6

x

Obsessive-compulsive Disorder (OCD): “Medication is often prescribed for
individuals with OCD. Psychotherapy can be helpful in learning ways to feel
more in control, cope better with stressors, and explore the underlying issues
associated with the obsessive thoughts.”6

x

Panic Disorder (with or without Agoraphobia): “Although medication can be
useful, psychotherapy (especially behavioral and cognitive/behavioral approaches
have proved quite successful). The key to treatment is accepting the panic attacks
as psychological rather than physical (once these causes have been ruled out by a
physician), practicing relaxation exercises, and working through the underlying
issues.”6

x

Phobias (including Social Phobia): “Treatment is often behavioral in nature, with
the therapist guiding the client through exercises more closely resembling the
feared object or situation. Exploring underlying issues can also be beneficial.”6

x

Post-traumatic Stress Disorder (PTSD): “Psychological treatment is considered
the most effective means to recovery from PTSD, although some medications
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(such as anti-anxiety meds) can help alleviate some symptoms during the
treatment process.”6
An Overview of Cost of Illness Analysis
Description of Cost of Illness Analysis
According to Joel & Segel, “Cost-of-illness studies measure the economic burden
of a disease or diseases and estimate the maximum amount that could potentially be
saved or gained if a disease were to be eradicated.”3(p. 2) Both direct and indirect costs are
included in a comprehensive analysis. However, based on the perspective of a study,
either of these cost categories can be excluded.3
Direct and indirect costs. Direct costs refer to the opportunity cost of resources
used for treating a particular disease. However in measuring indirect costs, the main
focus is on the value of resources lost due to a particular disease.31 According to Hodgson
and Meiners, opportunity cost is defined as “the value of the forgone opportunity to use
in a different way those resources that are used or lost due to illness.”3(p. 4)
Direct costs include direct medical costs and nonmedical direct costs. Direct
medical costs include costs for hospital inpatient stays, emergency room visits, officebased medical visits, outpatient visits, prescription medication, nursing home care,
hospice care, rehabilitation care, home health care, and cost for medical supplies.31,32
Nonmedical direct costs include costs due to transportation to health care facilities;
relocation and any other change in one’s life pattern due to the illness.3 Indirect costs
include mortality cost (cost of premature death due to the illness) and morbidity cost
(productivity loss).
There are studies in which intangible costs i.e. costs of pain and suffering are
included in the analysis as well. However, estimation of intangible costs is less common
due to difficulty in measuring these costs.3
Perspective. One of the most important aspects of any economic evaluation is the
perspective of the study. In fact, inclusion and exclusion of the above discussed cost
categories depend on the perspective undertaken in the study. There are several different
perspectives that can be used in economic evaluations. For instance, one perspective
measures the costs to the society (societal perspective) and another one may take into
account costs to the third party payer (payer perspective). There are other perspectives in
which costs to businesses, the government, and participants and their families are
included.4,31
Incidence-based versus prevalence-based approach. In an incidence-based
study, the attempt is to estimate the lifetime cost for a patient with a particular illness.
Here the lifetime cost refers to the cost of an illness from diagnosis to cure or death. On
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the other hand, in prevalence-based studies, all costs for a particular population in a given
time period (regardless of the date of onset) will be measured. Requiring less data and
fewer assumptions than incidence-based studies, prevalence based studies are far more
common.3
Measuring indirect costs. There are three primary approaches to estimate
indirect costs including the Human Capital approach (HCA), the friction cost method,
and the willingness to pay approach. In the HCA, the lost production for employed
patients/caregivers is measured in terms of lost earnings.33,34 If the patient/care giver is
not employed, the value of household work would be equivalent to the cost of hiring a
replacement from the labor market.3
Friction cost method is a more realistic approach to measure indirect costs. The
assumption here is that as long as unemployment rate is greater than zero, the market
would be able to replace the lost work force. So, the loss of an employee will lead to
production loss until the new employee is hired and trained.35-37 This period is called the
friction period.
Finally, indirect costs can be measured using the willingness to pay approach.
According to Joel & Segel, “The willingness to pay approach measures the amount an
individual would pay to reduce the probability of illness or mortality.”3(p. 14)
Top-down or bottom-up approach. In top-down approach, highly aggregated
data sources (on population-level) would be directly used. While in bottom-up approach,
the individual-level data (adopted from patients, patient’s chart, epidemiological
registries or cohort studies) would be aggregated to get the population-level data.38
History of Cost of Illness Studies
Cost-of-illness studies were among the first economic evaluation studies and first
appeared in the literature in 1913 in a paper called The value of human life.39 Later in the
1950s and 1960s, other researchers tried to develop the cost of illness methodology
further.34,40,41
In 1959, Mushkin and Collings tried to clarify cost concepts in cost of illness
studies. They introduced a classification of costs “based on their effects on the use,
distribution, and quantity of economic resources”.40(p. 795) In 1966, Dorothy Rice
developed a framework for calculating single-year costs of illness, disability, and death
by major category of illness, using existing data sets. She also tried to address the
problems in which a researcher encounters in measuring direct and indirect costs.34 Later,
this method became a standard approach for conducting a cost of illness study. Since
1966, Rice has updated and refined her methodology.
Cost of illness studies became more popular in the 1970s and 1980s, when they
were used to gain support for more resources being devoted to health care.42 Later in
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1990s, pharmaceutical companies started to use cost of illness studies to highlight the
economic burden of a particular disease. The aim was to justify the fact that more
resources, i.e. the company’s product, should be devoted to that particular disease.42
Nowadays, cost of illness studies are being widely used by health economists,
pharmaceutical companies, clinicians, and policymakers to set research agendas and
allocate resources.4,5
Review of Cost of Illness Studies for Anxiety Disorders
An overview of the literature on cost of illness studies for anxiety disorders
revealed that there are quite a few studies in this field. In general, these studies form up
two separate categories. One category includes the studies in which the main purpose was
to calculate the cost of illness for anxiety disorders. This category by itself has two
different subcategories: cost of illness studies for multiple diagnoses of anxiety disorders,
and cost of illness studies for a particular diagnosis of anxiety disorder. Another major
category consists of studies in which obtaining the cost of illness was not the main
purpose of the study. For instance, some have calculated the cost as part of a costeffectiveness study for a particular treatment of anxiety disorders, while some tried to
determine the predictors of cost for anxiety disorders.
Studies in Which the Main Purpose Was to Calculate COI for Anxiety Disorders
In this section, studies with the objective of calculating cost of illness for anxiety
disorders are reviewed.
COI studies for multiple diagnoses of anxiety disorders. DuPont et al.5 and
Greenberg et al.10 estimated the direct and indirect costs of anxiety disorders in U.S. in
1990s. Goetzel et al.11 assessed the health and productivity cost burden of the top ten
physical and mental health conditions, including anxiety disorders, affecting six large
U.S. employers; while Marciniak et al.15 tried to estimate the cost of anxiety disorders
among the employed individuals in the United States. Andlin-Sobocki et al.13 conducted a
study to estimate the cost of anxiety disorders in Europe and Smit et al.14 estimated the
costs of nine common mental disorders, including anxiety disorders, in Netherlands.
COI studies for a particular diagnosis of anxiety disorders. Siegel et al.,24
Leon et al.,16 and Batelaan et al.28 assessed the costs of panic disorder in the U.S., and
Netherlands, respectively. While Patel et al.27 and Acarturk et al.29 estimated the
economic consequences of social phobia in the Great Britain and Netherlands. Rees et
al.17 compared medical utilization and costs incurred by people with panic disorder to
those incurred by people with social phobia.
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Studies in Which Obtaining the COI Was Not the Main Purpose of the Study
Below is the list of studies falling in this category:
x

Salvador-Carulla et al.26 estimated the costs before and after the diagnosis and the
provision of effective treatment for panic disorder.

x

Souetre et al.25 examined how co-morbidity and symptom severity related to the
costs of generalized anxiety disorder (GAD).

x

Marciniak et al.18 examined the different clinical and demographic characteristics
that could affect the cost of treating patients with anxiety disorders.

x

Roberge et al.23 examined healthcare services utilization and costs before and
after providing an empirically supported cognitive-behavioral treatment for panic
disorder with agoraphobia.

x

McLaughlin et al.20 conducted a study aimed at measuring the impact of having
both depression and anxiety, having neither or either condition alone on treatment
patterns, health care utilization, and cost.

x

Stein et al.21 tried to find out how antidepressant adherence, among patients with
anxiety disorders, will affect medical resource use and costs.

x

Olfson and Gameroff 22 conducted a study to evaluate the extent to which pain
severity contributes to the health care costs of patients with generalized anxiety
disorder (GAD).

Specific Features of the COI Studies for Anxiety Disorders
In the following sections, each of the above-mentioned studies is assessed with
respect to the main features of a cost of illness analysis.
Source of data. In order to get data on resource use and cost, almost half of the
studies used retrospective cohort study methodology. In some of these studies, patients
were asked retrospectively about their utilization,16,17,24,25,29 while in other studies,
medical databases providing individual information on healthcare utilization and cost
were used to obtain required data.5,10,11,13,15,18,20,21 Table 2-2 shows the list of these
databases.
Top-down or bottom-up approach. Only two studies used the top-down
approach to calculate cost of illness for anxiety disorders.5,10 Other studies used the
bottom-up approach.
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Table 2-2.

Data sources used in COI studies of anxiety disorders.

Authors
DuPont et al.5

Data source
National Institute of Mental Health (NIMH)
National Hospital Discharge Survey
American Medical Association
National Center for Health Statistics
National Nursing Home Survey
Pharmaceutical Data Source

Greenberg et al.10

National Comorbidity Study (NCS)
A large staff–model health maintenance organization
The U.S. Bureau of the Census
Professional associations and news periodicals
National Center for Health Statistics
Industry sources

Goetzel et al.11

Health and Productivity Management (HPM)a Subset of
MedStat’s MarketScanb Database

Andlin-Sobocki13

German National Health Interview and Examination
Survey - mental health supplement (GHS–MHS)c

Marciniak et al.15

Health and Productivity Management (HPM) Subset of
MedStat’s MarketScan Database

McLaughlin et al.20

PharMetrics Patient-Centric Databased

Stein et al.21

Integrated Healthcare Information Services National
Managed Care Benchmark Databasee

a

The HPM database contains workplace absence, short-term disability, and worker
compensation data for six fortune 200 U.S. employers.
b
The Market- Scan database is an annual medical database that includes private sector
health data from approximately 100 payers and contains data on clinical utilization,
expenditures, and enrollment across inpatient, outpatient, prescription drug, and carve-out
services. This database links paid claims and encounter data to detailed patient
information across sites and types of providers over time.
c
The survey was carried out in 1998/99 and included a community sample of 4181 (age:
18–65) individuals.
d
PharMetrics Patient-Centric database is composed of medical and pharmaceutical
claims for approximately 36 million patients from 61 health plans across the United
States.
e
Located in Waltham, Massachusetts, this nationally representative database includes
data from 30 health plans covering more than 25 million persons.
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Perspective of the study. Eight out of twenty one studies used payer
perspective,11,15-17,19-22 while other studies used societal perspective.
Cost categories. More than half of the studies included indirect costs in their
analysis as well as direct costs. To estimate indirect costs, all studies used HCA. Only
four studies gave an estimation of indirect costs on a population level (employed or
unemployed patients).5,13,29,43 The rest reported indirect costs based on employed patients
only.10,11,14,15,24-28 Specific cost categories used in these studies are shown in Table 2-3.44
As one can see, the most frequent cost categories included in the analysis were outpatient
treatment cost, costs for hospital treatment, drugs, and emergency room facilities. Studies
conducted by DuPont et al.5 and Greenberg et al.10 were the most comprehensive studies
with respect to cost categories included in the analysis.
Incremental cost approach. In estimating the cost of illness for anxiety
disorders, less than half of the studies calculated the incremental healthcare cost of
individuals with anxiety disorders, in excess of those who were anxiety free. In other
words, not only costs directly due to anxiety disorders were included, but also costs due
to comorbidities and complications of anxiety disorders were considered in their cost
estimation;14,15,17,18,20,22,24,27,29 Rest of the studies only estimated the costs which were
directly due to anxiety disorders.
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Table 2-3.

Cost categories included in cost of illness studies.
Direct costs

Mortality

9

9

9

9

9
9
9
9

9
9
9

9
9
9

9

9

9

9

9

9

9
9
9
9

9
9
9
9

9
9
9
9

Stein et al.
Batelaan et al.28
Olfson and Gameroff 22

9
9
9
9
9
9
9
9
9
9

9
9
9
9
9
9
9
9
9

Acarturk et al.29

9

9
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Early retirement

9
9
9
9
9
9
9
9
9

Sick-leave

9

9
9
9

Marciniak et al.15
Marciniak et al.18
Andlin-Sobocki et al.13
Panzer et al.19
Roberge et al.23
McLaughlin et al.20
Smit et al.14

Productivity loss

Souetre et al.25
Salvador-Carulla et al.26
DuPont et al.5
Leon et al.16
Rees et al.17
Greenberg et al.10
Patel et al.27
Goetzel et al.11

Non-medical

Siegel et al.
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ER

Edlund and Sawn43

Rehabilitations

Medications

Inpatient

Outpatient

Authors

Indirect costs

9
9
9
9
9

9

9

9
9

9
9

9

9
9

9
9
9
9
9
9
9

9

9

9

9

9

9

9

ER = Emergency Room.
Source: Konnopka A, Leichsenring F, Leibing E, Konig HH. Cost-of-illness studies and
cost-effectiveness analyses in anxiety disorders: a systematic review. Journal of Affective
Disorders. Apr 2009; 114(1-3):14-31.
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CHAPTER 3.

METHODOLOGY

Research Design
In order to estimate the cost of illness for anxiety disorders, a retrospective
database analysis was conducted. The specific features of the research are as follows:
Perspective
Cost of illness for anxiety disorders was calculated from a societal perspective. In
other words, this economic evaluation includes the impact of anxiety disorders on the
welfare of the whole society. In order to achieve this goal, both direct and indirect costs
attributable to anxiety disorders have been estimated. The costs components included in
this study are as follow:
x

Direct medical costs: This category refers to expenditures for inpatient visits,
outpatient visits, office-based medical provider visits, emergency room visits,
prescription medications, and other medical expenses (other medical expenses
refer to expenses not included in the above-mentioned categories, such as
expenditures for home health and medical devices and supplies).

x

Indirect costs: This category includes morbidity and mortality costs.

Approach
To estimate cost of illness, one can take either incidence-based or prevalencebased approach. As it was mentioned in the previous chapter, prevalence-based approach
is far more common, since it needs less data and time in comparison with the incidencebased one. So in this research, a prevalence-based approach was adopted to estimate the
cost of illness for anxiety disorders.
Data
Data was collected from three major databases. These databases are explained in
details in the “Data Overview” section.
x

Medical Expenditures Panel Survey (MEPS).

x

The Bureau of Labor Statistics (BLS).

x

The National Vital Statistics System (NVSS).
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Table 3-1 shows the exact databases used for calculation of each cost component.
Using these databases, the researcher estimated costs at individual level. The bottom-up
approach was undertaken to aggregate individual-level data to population-level.
Sampling
MEPS sampling plan. The study sample was based on the MEPS sampling plan.
As it was mentioned in chapter 2, MEPS collects data on health services utilization and
cost, as well as how frequently these services are used and how they are paid.45
MEPS currently has two major components: the Household Component and the
Insurance Component. The Household Component provides data from individual
households and their members, which is supplemented by data from their medical
providers. The Insurance Component is a separate survey of employers that
provides data on employer-based health insurance. The Household Component
(HC) collects data from a sample of families and individuals in selected
communities across the United States, drawn from a nationally representative
subsample of households that participated in the prior year's National Health
Interview Survey (conducted by the National Center for Health Statistics). During
the household interviews, MEPS collects detailed information for each person in
the household on demographic characteristics, health conditions, health status, use
of medical services, charges and source of payments, access to care, satisfaction
with care, health insurance coverage, income, and employment.45
Table 3-1.

Data sources for calculation of each cost component.

Cost component
Direct Medical Cost

Data source
MEPS Data Files including:
Full Year Consolidated Data File
Medical Conditions File
Prescribed Medicines File
Hospital Inpatient Stays File
Emergency Room Visits File
Outpatient Visits File
Office-based Medical Provider File
Home Health Services File
Other Medical Expenses File

Indirect cost: Morbidity

MEPS Full Year Consolidated Data File
Bureau of Labor Statistics (BLS)

Indirect cost: Mortality

The National Vital Statistics System (NVSS)
Bureau of Labor Statistics (BLS)
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In this study, only the household component has been used. Each year, the
selected households from the prior year's National Health Interview Survey (NHIS) form
a panel. Each panel is followed for a period of two years. During these two years, each
household in the panel is interviewed in five rounds. Consequently, the sample for each
year of the MEPS data files includes two overlapping panels. Figure 3-1 shows this
overlapping panel design.46
Sample size. When using national data, a sufficient sample size must be obtained
to ensure reliable survey estimates; Medical expenditure data are highly skewed. It means
that a small portion of population accounts for a large portion of expenses. Medical
expenditure data from MEPS follow the same pattern. Consequently, if the sample size is
not large enough, “some point estimates for particular subgroups of the population may
show substantial fluctuations from one year to the next that are not statistically
significant.”47(p. 2615) To address this issue, the Agency for Healthcare Research and
Quality (AHRQ) has set the minimum requirement of 100 un-weighted participants per
cell for producing national estimates.47
Even though MEPS annual sample size is much larger than 100, the number of
participants in many of the MEPS analytic and policy relevant subpopulations of interest
might be less than 100. Fortunately, several consecutive years of MEPS data files can be
pooled together to improve the precision of estimates and expand the types of analyses
Panel 14
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Figure 3-1.

Overlapping design of MEPS sample.

Source: MEPS HC-138: 2010 Full Year Consolidated Data File. 2012;
http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h138/h138doc.shtml#2581
UnitedStates. Accessed 10/15/2012.
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possible.
For this research, data was pooled from the 2009-2010 MEPS public use files, to
allow for a large enough sample size. 2009 and 2010 data were the latest available MEPS
datasets at the time of study. More specifically, data files used in this study were: full
year consolidated data file; medical conditions file; as well as event level files for
prescribed medicines, hospital inpatient stays, emergency room visits, outpatient visits,
office-based medical provider visits, home health visits, and other medical expenses from
2009 and 2010 MEPS-Household Components. The pooling was conducted according to
the MEPS guidelines on pooling several years of data.48
Study sample. The study population is consisted of all survey-respondents (for
the years 2009 and 2010) 18 years and older, with positive person weights. Among these,
individuals who reported a diagnosis of, or had a medical event associated with anxiety
disorder(s) were classified as anxiety patients. Diagnoses and events were identified
using Clinical Classification (CC) code. CC code aggregates conditions and procedures
into mutually exclusive and clinically homogeneous categories, using Clinical
Classification Software.49 The CC code 651 is specifically assigned to anxiety disorders.
The conditions included in this category are: generalized anxiety disorder, panic disorder,
phobias (social phobia, specific phobia), agoraphobia, obsessive-compulsive disorder,
post-traumatic stress disorder, acute stress disorder, overanxious disorder, and mixed
emotional disturbances.
Data Overview
As it was mentioned earlier, three major databases were used in this study as data
sources. Information collected from each of these data bases is provided in the following
sections:
MEPS Data Files
The majority of data was collected from MEPS:
MEPS is a set of large-scale surveys of families, individuals, their medical
providers and employers across the United States. It is jointly sponsored by the
Agency for Healthcare Research and Quality (AHRQ) and the National Center for
Health Statistics (NCHS), and has been conducted annually since 1996. It has
three major components; the Household Component (HC), the Insurance
Component (IC), and the Medical Provider Component (MPC). The MEPS-HC
collects data from a nationally representative sample of the civilian noninstitutionalized population of the U.S.; and is intended to provide national
estimates of healthcare utilization, cost, insurance cover- age, and sources of
payment.50(p. 721)
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The following MEPS data files were used in this research:
x

Full Year Consolidated Data file: Each year, the Full Year Consolidated Data file
provides information collected on a nationally representative sample of the
civilian non-institutionalized population of the United States for that calendar
year. More specifically, this file contains the following variables: survey
administration, language of interview, demographics, parent identifiers, health
status, disability days, access to care, employment, quality of care, patient
satisfaction, health insurance, use, income, and expenditure variables.

x

Medical Conditions file: For each calendar year, the Medical Conditions file
provides information on household-reported medical conditions.

x

MEPS Household Component Event files: There are seven event-level files in
MEPS Household Component which provide information on utilization and
expenditure, due to medical conditions, by type of health services received. These
files are: Prescribed Medicines file, Dental Visits file (not used in this study),
Other Medical Expenses file, Hospital Inpatient Stays file, Emergency Room
Visits file, Outpatient Visits file, Office-Based Medical Provider Visits file, and
Home Health file.

Variables used in analyses from MEPS data files. List of variables from these
data files, which were used in the analyses, are provided in Table 3-2. Some of these
variables are categorical while others are continuous. List of categorical variables, along
with levels of each variable, is provided in Table 3-3.
Summary variables. According to the MEPS survey design, each year
interviewers collect data through three consecutive rounds (for each panel). Consequently
for most measures, MEPS has information in each round (round-level variables) and also
at the end of year. However, some variables are presented only at round-level and the
researcher needs to summarize them into single variables representing the status of a
whole year. In this section, list of summary variables used in the analyses and the way
they were constructed are provided.
x

Perceived health status (RTHLTH), Sick-leave pay (SICPAY), union status
(UNION), and occupation category (OCCCAT): The value of summery variable
would be equal to the most frequent value of round variables. If round variables
all have different values, then round variable with the longest reference period
represents the summery variable.

x

Number of days missed work due to illness/injury (DDNWRK) and number of
days stayed in bed due to illness/injury (DDBDYS): Summery variable is equal to
the sum of round-level variables.

x

Employment status (EMPST): In MEPS, a current main job is defined for persons
who either reported they were currently employed and identified a current main
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Table 3-2.

List of variables in MEPS data files used in the current study.

Variable name
DUPERSID

Description
Person ID

Source
Consolidated Data File

PANEL

Panel Number

Consolidated Data File

PERWT10F

Final Person Weight,

Consolidated Data File

VARSTR

Variance Estimation Stratum

Consolidated Data File

VARPSU

Variance Estimation PSU

Consolidated Data File

SEX

Sex

Consolidated Data File

AGELAST

Person’s Age Last Time Eligible

Consolidated Data File

RACEX

Race

Consolidated Data File

HISPANX

Hispanic Ethnicity

Consolidated Data File

HIDEG

Highest Degree Attained

Consolidated Data File

POVCAT10

Family Income as Percent of Poverty Line

Consolidated Data File

MARRY10X

Marital Status

Consolidated Data File

REGION10

Census Region

Consolidated Data File

MSA10

MSA Status

Consolidated Data File

RTHLTH31

Perceived Health Status RD 31*

Consolidated Data File

RTHLTH42

Perceived Health Status RD 42*

Consolidated Data File

RTHLTH31

Perceived Health Status RD 53*

Consolidated Data File

TOTEXP10

Total Healthcare Expenditure

Consolidated Data File

ERTEXP10

Total ER Expenditure

Consolidated Data File

OPTEXP10

Total Outpatient Expenditure

Consolidated Data File

OBVEXP09/10

Total Office-Based Visits Expenditure

Consolidated Data File

IPTEXP10

Total Hospital Inpatient Expenditure

Consolidated Data File

RXEXP10

Total RX Expenditure

Consolidated Data File

OTHEXP10

Total Equipment/Supply Expenditure

Consolidated Data File

HHNEXP09/10

Consolidated Data File

HHAEXP09/10

Total Home Health Non-Agency
Expenditure
Total Home Health Agency Expenditure

DDNWRK31

# Days Missed Work RD 31 *

Consolidated Data File

26

Consolidated Data File

Table 3-2.

(Continued).

Variable name
DDNWRK42

Description
# Days Missed Work RD 42 *

Source
Consolidated Data File

DDNWRK53

# Days Missed Work RD 53 *

Consolidated Data File

WKINBD31

# Days Stayed in Bed RD 31 *

Consolidated Data File

WKINBD42

# Days Stayed in Bed RD 42 *

Consolidated Data File

WKINBD53

# Days Stayed in Bed RD 53*

Consolidated Data File

EMPST31

Employment Status RD 31*

Consolidated Data File

EMPST42

Employment Status RD 42*

Consolidated Data File

EMPST53

Employment Status RD 53*

Consolidated Data File

HRWG31X

Hourly Wage RD 31 *

Consolidated Data File

HRWG42X

Hourly Wage RD 42 *

Consolidated Data File

HRWG53X

Hourly Wage RD 53 *

Consolidated Data File

SELFCM31

Self-Employed RD 31 *

Consolidated Data File

SELFCM42

Self-Employed RD 42 *

Consolidated Data File

SELFCM53

Self-Employed RD 53 *

Consolidated Data File

UNION31

Union Status RD 31 *

Consolidated Data File

UNION42

Union Status RD 42 *

Consolidated Data File

UNION53

Union Status RD 53 *

Consolidated Data File

SICPAY31

Paid Sick Leave RD 31*

Consolidated Data File

SICPAY42

Paid Sick Leave RD 42*

Consolidated Data File

SICPAY53

Paid Sick Leave RD 53 *

Consolidated Data File

NUMEMP31

Number of Employees RD 31 *

Consolidated Data File

NUMEMP42

Number of Employees RD 42 *

Consolidated Data File

NUMEMP53

Number of Employees RD 53 *

Consolidated Data File

OCCCAT31

Occupation Group RD 31 *

Consolidated Data File

OCCCAT42

Occupation Group RD 42 *

Consolidated Data File

OCCCAT53

Occupation Group RD 53 *

Consolidated Data File

INS10X

Insurance Indicator Variable

Consolidated Data File

27

Table 3-2.

(Continued).

Variable name
INSCOV10

Description
Health Insurance Coverage Indicator

Source
Consolidated Data File

MCAID10X

Covered by Medicaid

Consolidated Data File

MCARE10X

Covered by Medicare

Consolidated Data File

TRICR10X

Covered by Tricare

Consolidated Data File

OTPUBA10,
OTPUBB10,
STAPR10
PUB10X

Covered by Other Public Insurances

Consolidated Data File

Covered by Public Insurance

Consolidated Data File

CONDIDX

Condition ID

ICD9CODX

ICD-9-CM Code For Condition

CCCODEX

CC Code in Conditions File

RXCCC1X-3X

CC Code in RX File

Medical Conditions
File
Medical Conditions
File
Medical Conditions
File
RX File

ERCCC1X-3X

CC Code in ER Visit File

ER visits File

OPCCC1X-4x

CC Code in Outpatient Visit File

Outpatient Visits File

IPCCC1X-4X

CC Code in Hospital Inpatient File

Hospital Inpatient File

OBCCC1X-4X

CC Code in Office-Based Visit File

Office-Based Visits
File

Notes: Name of variables in this table are as shown in MEPS 2010 data files. In the
previous years of MEPS data files, most variables have the same names. Variables ending
in 10 represent the values as of 12/31/2010. So for each year of data collection, these
variables would end in XX, where XX are the last two digits of the year data was
collected for; Variables ending in 31, 42, or 53 are round specific variable and the last
two digits at the end specify the round in which data was collected (i.e. round 1, 2, 3 of
the panel started in the current year (the first digit) or round 3, 4, 5 of the panel started in
the previous year (the second digit)).
* These variables haven’t been used directly in the analyses. Instead, they have been used
to construct summary variables, and the summary variables were included in the
analyses.
PSU=Primary Sampling Unit; MSA = Metropolitan Statistical Area; RD = Round; ER =
Emergency Room; RX = Prescribed Medicine; # = Number; CC = Clinical Classification.
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Table 3-3.

List of categorical variables.

Variable(s)
Sex

Level
1
Male
2
Female

Value

AGE CATEGORYa

1
2
3
4

18-24
25-44
45-64
65+

RACE/ETHNICITYb

1
2
3
4

White-non Hispanic
Black-non Hispanic
Hispanic
Other

REGION10

1
2
3
4

Northeast
Midwest
South
West

MSA10

1
2

Non-MSA
MSA

POVCAT10
(Poverty Category)

1
2
3
4
5

Poor
Near poor
Low income
Middle income
High income

MARRY10X
(Marital Status)

1
2
3

Married
Widowed/Divorced/Separated
Never Married

INSCOVc
(Insurance Coverage)

1
2
3
4
5
6

Uninsured
Dual Eligible
Medicare
Medicaid
Other Public
Private

SELFCM
UNION
SICPAY

1

Yes

2

No
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Table 3-3.

(Continued).

Variable(s)
EMPST31/42/53
(Employment Status)

Level
1
2
3
4

Value
Currently employed
Has a job to return to
Employed during the reference period
Not employed with no job to return to

OCCCAT
(Occupation Category)

1
2
3
4
5
6
7
8

Management, business, and financial operations
Professional and related occupations
Service occupations
Sales and related occupations
Office and administrative support
Farming, fishing, and forestry
Construction, extraction, and management
Production, Transportation, and material moving

HIDEG
(Education)

1
2
3
4
5

No degree
GED/High school diploma
Bachelor’s degree
Master/PhD
Other degree

RTHLTH
(Perceived Health Status)

1
2
3
4
5

Excellent
Very good
Good
Fair
Poor

CCIfreq
(D’Hoore Adaptation of
Charlson Comorbidity
Index)d

0
1
2
3

Zero comorbidity
One comorbidity
Two comorbidities
Three or more comorbidities

Note: The levels reported for some categorical variables here, do not exactly match the
levels originally provided in MEPS data files. For some variables, we had to combine two
or more levels to summarize data, or to get enough sample size in each level.
a
This variable was constructed using the continues variable “AGELAST”; b This variable
was constructed using “RACEX” and “HISPANX” variables; c This variable was
constructed using the following variables: INS10X, INSCOV10, MCAID10X,
MCARE10X, TRICR10X, OTPUBA10, OTPUBB10, STAPR10, and PUB10X; d This
variable was constructed using ICD-9-CM cods, according to the conditions and weights
listed in the D’Hoore adaptation of CCI.
GED = Graduate Equivalency Degree; MSA = Metropolitan Statistical Area.
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job (at the time of interview), or those who reported and identified a job to return
to. So, If an individual had a current main job for at least one round in year (at
least one of the round-level variables was equal to 1 or 2), then he/she was
considered as being employed (EMPST=1).
x

Hours worked per week (HOUR), number of employees (NUMEMP), and hourly
wage (HRWG): Summery variable is equal to the mean of round-level variables.

x

Self- employment status (SELFCM): For employed individuals, If at least in one
of the reported current main jobs, the person was self-employed, he/she is
considered as self-employed (SELFCM=1).

BLS Data
“The Bureau of Labor Statistics (BLS) is an independent national statistical
agency that collects, processes, analyzes, and disseminates essential statistical data to the
American public, the U.S. Congress, other federal agencies, state and local governments,
business, and labor. The BLS also serves as a statistical resource to the Department of
Labor.”51 Examples of information that BLS provides are: employment cost trends,
national compensation data, wages by area and occupation, earnings by demographics,
earnings by industry, employee benefits …
The specific information collected from BLS is:
x

Weekly & Hourly Earnings:52 The BLS reports (median) weekly earnings by
industry type, occupation type, sex, race, ethnicity, age, education level, class of
worker and labor force status. This information is based on the Current Population
Survey (CPS).The CPS is a monthly survey of households (the sample represents
the civilian non-institutional population of the U.S.) conducted by the Bureau of
Census for the BLS. It provides a comprehensive body of data on the labor force,
employment, unemployment, persons not in the labor force, hours of work,
earnings, and other demographic and labor force characteristics.

x

Labor Force Statistics:53 The data contains Labor Force Participation Rate (LFPR)
by age, race, and gender. This information is also based on the CPS.

x

Healthcare component of the Consumer Price Index(CPI) as well as CPI for all
items: This information is available in the CPI Detailed Report Data for March
2013.54

NVSS Data
The National Center for Health Statistics (NCHS) is a component of the Centers
for Disease Control and Prevention (CDC), and “its mission is to provide statistical
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information that will guide actions and policies to improve the health of the American
people. To carry out its mission, NCHS conducts a wide range of annual, periodic, and
longitudinal sample surveys and administers the National Vital Statistics Systems.”55 The
NVSS collects data on vital events including births, deaths, marriages, and divorces in
the United States. The researcher used the following reports to collect required data.
Number of deaths due to anxiety disorders were extracted from the first three reports,
while the fourth one was used to collect information on life expectancy.
x

Deaths, percent of total deaths, and death rates for the 15 leading causes of death
in 5-year age groups, by race and sex: United States, 1999-2010.56

x

Deaths, percent of total deaths, and death rates for the 15 leading causes of death
in 10-year age groups, by Hispanic origin, race for non-Hispanic population and
sex: United States, 2010.57

x

Deaths, percent of total deaths and rank order for 113 selected causes of death and
Enterocolitis due to Clostridium difficile, by Hispanic origin, race for nonHispanic origin and sex, United States, 2010.58

x

Deaths: Final data for 2010.59
Analysis Technique

In this section, the analysis technique for each specific aim of the study is
explained.
SA1: Estimating the Societal Cost of Anxiety Disorders for the U.S. Adult
Population
According to Equation 3-1, the societal cost of anxiety disorder(s) is equal to
summation of its direct and indirect costs.
Total cost = Overall direct medical cost + Indirect cost

(Eq. 3-1)

In the following sections, the methodology used to estimate each component of
Equation 3-1 is explained.
Overall direct medical cost. Overall direct medical cost incorporates costs due to
prescription medications, office-based medical provider visits, inpatient visits, outpatient
visits, ER visits, and other medical expenses. In this section, we explain the methodology
used to estimate the overall direct medical costs due to anxiety disorders. Estimating
direct medical cost by category of health service (SA2), is explained in the next section.
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To estimate overall direct medical expenditures attributable to anxiety disorders,
we used the incremental cost approach. This method, suggested by the AHRQ for
estimating cost of illness with MEPS data, has been widely used by previous
researchers.60-66 The incremental cost approach provides an estimate of diseaseattributable expenses by calculating expenditures incurred by a disease population in
excess of those incurred by a disease free population. This difference in expenses by the
two populations represents the total cost of illness, including treatment expenses, as well
as expenses related to complications of the disease and its comorbidities.65 To adjust for
potential differences in socioeconomic and clinical characteristics of the two populations,
which are considered to have an impact on cost, a multivariate regression analysis is
conducted. As such, this approach estimates expenditures solely associated with the
disease of interest.64
To estimate direct medical costs associated with anxiety disorders, first an
appropriate multivariate regression analysis needed to be developed to explain healthcare
costs through a set of explanatory variables. The outcome variable of the model was the
overall healthcare expenditure. Expenditure (cost) refers to what is actually paid for
healthcare services and is defined as the sum of direct payments by different sources such
as out-of-pocket payments, as well as payments by private insurance, Medicaid, and
Medicare. Expenditures are more accurate than charges for cost estimation purposes.
Charges vary from what is actually paid, due to uncollected liability, bad debt, charitable
care, and implementing contract negotiations.46
The main explanatory variable of the model was a disease- indicator variable,
indicating whether each individual in the sample suffered from anxiety disorder(s) or not.
Other covariates of the model were respondents’ gender, age, race/ethnicity, marital
status, education, poverty category, geographic region, metropolitan statistical area
(MSA), perceived health status (PHS), health insurance coverage, and the D’Hoore
adaptation of Charlson Comorbidity Index (CCI). The D’Hoore adaptation of CCI
controls for 17 medical conditions which are myocardial infarct, congestive heart failure,
peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary
disease, connective tissue disease, ulcer disease, mild liver disease, hemiplegia, moderate
or severe renal disease, diabetes , any tumor, leukemia, lymphoma, moderate or severe
liver disease, and metastatic solid tumor.67 These covariates were selected based on the
literature review and the availability of data in MEPS.
After developing and running the regression model, the estimated coefficients of
the model were used to calculate two predicted expenses for each individual. The first
predicted expenses assumed the individual had anxiety disorder(s) (by setting the diseaseindicator variable to one), and the second predicted expenses assumed the individual was
anxiety-free (by setting the disease-indicator variable to zero). The average per-person
increase in medical expenses attributable to anxiety disorders was calculated by taking
the difference in predicted expenses for each person and computing the weighted average
of the difference across the entire sample. Finally, the average per-person increase in
expenses was multiplied by the weighted number of individuals with anxiety disorders in
the sample, to get the total medical cost of anxiety disorders.
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In modeling healthcare cost data, the specific distributional characteristics of the
data must be taken into consideration. These characteristics are: (1) non-negative
observations; (2) excessive zero (i.e. there are a large number of individuals with zero
cost); and (3) highly skewed data (i.e. the majority of cost is incurred by a few patients).68
These characteristics make traditional Ordinary Least Square (OLS) regression inefficient
in modeling healthcare cost data. Alternatively, OLS with natural log-transformed cost
has been widely used to deal with heavily skewed data. However, this approach has some
limitations as well.68 First, the outcome variable is the logarithm of cost. So in order to
draw useful conclusions about the cost, the predicted values need to be retransformed
back to the original scale. While retransforming the outcome variable, by using smearing
factor, seems straightforward, interpretation of parameter estimates may still be
challenging. Second, in the presence of heteroskedasticity, using one smearing factor to
retransform the predicted values leads to biased estimates, i.e. under-estimation or overestimation of the actual cost. In such scenarios, a Generalized Linear Model (GLM), with
appropriate variance and link functions, is more efficient to model cost data. GLM
directly models both the variance and mean functions on the original scale of dependent
variable. As such, results can be interpreted with no need for retransformation from log
scale to the original scale.68 “The mean function, E(y|x) is represented as μ(xcβ), where μ
is the inverse link between the expectation of the observed raw-scale y and the linear
predictor xcβ.”68(p. 529) The link function generally used with healthcare cost data is the
log-link function.68 “Then μ is the exponential function. A commonly used family of
variance functions includes the power functions of the form v(x) = N (μ(xcβ))λ.”68(p. 529)
The specific type of variance functions depends on the value of λ. for instance, if the λ is
equal to 1 it means that variance is proportional to meant. So, it would be a Poisson like
model If the λ is equal to 2, it means that variance is proportional to mean squared, as in a
Gamma-like model.68
In order to find out which type of regression model was most appropriate for our
data, several diagnostics tests needed to be performed. First of all, we needed to find the
distribution of cost data to see if data was really skewed or not. Then, appropriateness of
using OLS regression with log-transformed data needed to be examined. This was
achieved by conducting the Breusch-Pagan/Cook-Weisberg test for heteroskedasticity.
One of the assumption of OLS is that variance of error terms (εj) should be constant (εj =
V2; for all j). If this assumption is violated, i.e. when heteroskedasticity is present, OLS
estimates are no longer the best linear unbiased estimator (BLUE). One of the major
consequences of heteroskedasticity is biased standard errors, in which leads to biased
inference, so results of hypothesis tests are possibly wrong. The Breusch-Pagan/CookWeisberg test for heteroskedasticity tests the linear heteroskedasticity.69 Their null and
alternative hypotheses are as follows:
H0: error variances are all equal
H1: error variances are a multiplicative function of one or more variables
In the case that heteroskedasticity was present; we needed to conduct a Park test
to see which variance function was more appropriate to be used in the context of GLM.
Park test was first introduced by Park in 1966, and its use is suggested in estimation of
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the relationship between the mean and the variance.68,70 In this regard, “the squared
residuals from a provisional model (GLM or log-transformed OLS) should be regressed
on the predictions (ŷ) from the same model, both log transformed.”68(p. 531) Equation 3-2
shows the regression model for Park test:
ln ((yi- ŷi)2) = λ0 + λ1 ln (ŷi) + QI

(Eq. 3-2)

Source: untin MB, Zaslavsky AM. Too much ado about two-part models and
transformation?: Comparing methods of modeling Medicare expenditures. Journal of
Health Economics. 5// 2004;23(3):525-542.
Morbidity cost. Indirect cost due to productivity loss (morbidity cost), have been
measured using the Human Capital Approach (HCA). In the HCA, productivity loss due
to an illness or injury is approximated by valuing the entire period of absence from work
by average individual’s earning. Equation 3-3 shows the formula used to estimate the
morbidity cost due to anxiety disorders:
Morbidity Cost ൌ ൬

σಿ
సభ ௪௧ כ௪ כ
σಿ
సభ ௪௧

൰ ݔ݊ܽܰ כ

(Eq. 3-3)

Where:
N = Total number of individuals in the sample.
Wti = Person weight for the ith individual in the sample.
Wgi = Daily wage for employed individuals and average daily wage for household
services if the individual is not employed.
ni = Number of missed work days (due to anxiety disorders) for employed individuals and
number of days stayed in bed (due to anxiety disorders) for unemployed individuals.
Nanx = Weighted number of individuals in the sample with anxiety disorder(s).
For individuals who were at paid employment for at least on round in year,
information on wage rates are available in the MEPS (in both Consolidated Data file and
Job file). For unemployed individuals, the period in which they had to stay in bed due to
an illness or injury was valued by average wage for private household services. Industries
in the private households are defined as those “engage in employing workers on or about
the premises in activities primarily concerned with the operation of the household. These
private households may employ individuals, such as cooks, maids, butlers, and outside
workers, such as gardeners, caretakers, and other maintenance workers.”71 Average wage
for private household services was obtained from the BLS.
Information on number of missed-work-days for employed individuals, (and
number of days an unemployed person had to stay in bed) due to each particular
condition, is not available in MEPS. Instead, MEPS collects this information for all
medical conditions an individual might have had in the survey year. So, we needed to
find out what portion of missed-work-days (variable WKINBD in MEPS consolidated
data file) and bed days (variable DDBDYS) were due to anxiety disorders. In this regard,
researcher used the same approach used to estimate the incremental cost. In other words,
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two separate multivariate regression analyses were conducted to estimate the incremental
number of missed work days/ bed days due to anxiety disorders. This approach has been
used by Akazawa, Sindelar, and Paltiel in their research on estimating the productivity
loss due to Influenza related illnesses.72
Outcome variables and the initial set of covariates for estimating the incremental
number of work days/ bed days due to anxiety disorders are provided in Table 3-4. These
covariates have been selected based on the relevant literature and availability of data in
MEPS.
After developing and running regression models, the estimated coefficients of
each model were used to calculate two outcomes for each individual. The first predicted
outcome assumed the individual had anxiety disorder(s) (by setting the disease-indicator
variable to one), and the second predicted outcome assumed that the individual was
anxiety-free (by setting the disease-indicator variable to zero). The per-person increase in
number of missed work days/ bed days attributable to anxiety disorders were calculated
by taking the difference in predicted outcomes for each person. Morbidity cost for each
individual in the study sample (per-person morbidity cost) was calculated by multiplying
the predicted outcome (i.e. predicted number of missed work days due to anxiety
disorders if the person was employed, and predicted number of bed days due to anxiety
disorders if the person was not employed), by the average daily wage of that person.
Table 3-4.
Outcome variables and the initial set of covariates for estimating the
incremental number of missed work days/ bed days due to anxiety disorders.
Regression Outcome
model
variable
Model 1
WKINBD

Sample for regression
analysis
Employed individuals in
the study population
(excluding selfemployed persons)a

Model 2

Unemployed individuals anx, gender, race/ethnicity,
in the study population
age, marital status, education,
poverty category, insurance
coverage, MSA, region, CCI.

WKINBD

a

Initial set of covariates
anx,b gender, race/ethnicity,
age, marital status, education,
poverty category, insurance
coverage, MSA, region, CCI,
number of employees, sickpay, union status, occupation
category

Self-employed individuals were excluded, since information such as sick-pay benefit is
not available for them.
b
anx represents the disease indicator variable.
MSA = Metropolitan Statistical Area, CCI = Charlson Comorbidity Index.

36

Average morbidity cost was estimated by taking the weighted mean of per-person
morbidity cost across the entire study sample. Finally, this average per-person cost was
multiplied by the weighted number of individuals with anxiety disorders in the sample to
get the total morbidity cost associated with anxiety disorders.
Mortality cost. Mortality cost is productivity loss due to premature deaths. In a
prevalence-based cost of illness study, productivity losses are “calculated for all patients
who die or become permanently disabled in the study year for that year and each year
until the expected age of death.”3(p. 9) In the HCA, mortality cost is the present value of
future earnings, from age of death to life expectancy. Lost future earnings due to a
medical condition can be estimated knowing the total number of deaths due to that
condition, and average annual wages of deceased individuals from the year they died to
their life expectancies.
In calculating mortality cost, it is assumed that “people will be working and
productive during their expected lifetime in accordance with the current pattern of work
experience”73(p. 283) (for their age/sex/race cohort). So, no assumption needed to be made
about the employment rate among deceased individuals. The researcher instead allowed
the actual employment experience of each age/sex/race cohort inform the calculations.
The estimated lifetime earnings (in present value terms) of a 25 year old White woman
would not be the same as that of a 40 year old Black man, in part because of different
LFPRs of these two cohorts. The LFPR in the BLS data already accounts for that source
of difference, so no further explicit assumption or adjustment needed to be made to
recognize the importance of this factor. LFPR is defined as the ratio of the civilian noninstitutionalized population who are in labor force by the civilian non-institutionalized
population who are eligible to be in labor force.
Another point to consider is that wages usually increase as individuals get more
experienced. So, average annual wage at time of death should be inflated to consider this
growth. According to BLS, 12-month increase in wages and salaries for the first quarter
of 2013 was equal to 1.6%.74 So, we assumed an increase of 1.6% in annual wages too.
Future annual earnings should then be discounted by an appropriate discount rate. The
most common discount rate used in the relevant literature is 3%, which is recommended
by the Panel on Cost Effectiveness in Health and Medicine.75 Current value of future
earnings should be calculated for all individuals who died due to the medical condition,
in the period of study, and then added up to get the mortality cost. In the case of anxiety
disorders, the researcher needed to know the number of suicides due to this medical
condition. It has been shown that 10% of suicides are due to anxiety disorders.5,10 So, we
multiplied the total number of suicides buy 10% to get the number of deaths.
The formula used to estimate the mortality cost associated with anxiety disorders
is shown in Equation 3-4.

 ܥܶܯൌ σ
ௗ

 כௐכሺଵǤଵሻିௗ
ሺଵାሻషಲ
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(Eq. 3-4)

Where:
MTC = Mortality cost for individuals who committed suicide due to anxiety disorders in
the period of study.
Ad= Age of death
Le= Life expectancy at age of death by race and gender.
Li= Labor force participation rate by gender and race at age i.
W= Average annual wage by gender and race at age of death.
r = Discount rate
SA2: Estimating the Incremental Direct Medical Expenditures Associated with
Anxiety Disorders by Service Category
Incremental direct medical expenditures associated with anxiety disorders for
different healthcare delivery settings were also estimated using the incremental cost
approach. We followed the exact same procedure used for estimating the overall
incremental cost. More specifically, several multivariate regression analyses were
developed to separately model inpatient visits expenditure, outpatient visits expenditure,
emergency room visits expenditure, prescription medications expenditure, office-based
visits expenditure, and other medical expenses. So for each model, the dependent variable
was the cost category of interest. Regression analyses were conducted on all individuals
in the study sample.
For all models, the same set of covariates was used. The main independent
variable of the models was the anxiety indicator variable (yes/no). Other covariates
included respondents’ gender, age, race/ethnicity, marital status, education, poverty
category, geographic region, metropolitan statistical area (MSA), perceived health status
(PHS), health insurance coverage, and the D’Hoore adaptation of Charlson Comorbidity
Index (CCI).
SA3: Estimating the Incremental Direct Medical Expenditures Associated with
Anxiety Disorders for Different Sub-populations
Incremental direct medical expenditures associated with anxiety disorders were
estimated for different sub-populations, using the incremental cost approach. These subpopulations were defined based on gender, age, race/ethnicity, marital status, education,
poverty category, region, MSA, and insurance coverage. Several multivariate regression
analyses were conducted to separately model overall healthcare cost for each group of
individuals. The dependent variable in all models was the overall healthcare cost. To
estimate the cost in each group, the regression analysis was conducted on that subpopulation only and therefore, the covariate identifying that sub-population was excluded
from the regression model. For instance, to estimate the incremental cost of anxiety
disorders among males, the regression analysis was conducted on males, excluding
gender from covariates of the model.
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We broke down the costs among Blacks and Whites even further by gender, age,
and geographic region (as you will see in the next chapter, cost of anxiety disorders was
not statistically significant for Hispanics. So, there was no point in looking at the cost of
anxiety disorders for Hispanics). The specific sub-populations in which incremental costs
of anxiety disorders were estimated for, along with covariates of each model are provided
in Table 3-5.
General Notes
For direct medical costs, all dollar amounts have been presented in 2013 dollars,
using the healthcare component of the CPI (for all urban consumers). Also, for morbidity
and mortality costs, all dollar amounts have been presented in 2013 dollars, using the CPI
(for all urban consumers), for all items. The formulas used to present cost data from
2009/2010 dollars to 2013 dollars are provided below:
$2009 * (CPI2013 / CPI2009) = $2013
$2010 * (CPI2013 / CPI2010) = $2013
Where:
$2009 = Cost in 2009 dollars.
$2010 = Cost in 2010 dollars.
$2013 = Cost in 2013 dollars.
For direct medical cost:
CPI2009 = Healthcare Component of CPI for the year 2009 = 379.51654
CPI2010 = Healthcare Component of CPI for the year 2010 = 391.04654
CPI2013 = Healthcare Component of CPI for the year 2013 = 424.15454
For morbidity and mortality costs:
CPI2009 = CPI for all items for the year 2009 = 212.70954
CPI2010 = CPI for all items for the year 2010 = 217.63154
CPI2013 = CPI for all items for the year 2013 = 232.77354
All statistical analyses were conducted using SAS software version 9.3 (SAS
Institute, Cary, NC)76 and STATA software version 12.77
All analyses accounted for the complex survey design of MEPS to obtain
national-level estimates. Furthermore, subpopulation analysis was conducted to generate
results for individuals 18 years and older. Thereby, all results are projected to the
ambulatory adult population of the U.S.
The p-value threshold was set at 0.05 to determine statistical significance of twotailed tests.
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Table 3-5.

Sub-populations along with model specifications.
Covariates
Poverty cat

Region

MSA

Health Ins

PHS

CCI

a

Education

Race*Gender*Age

Marital status

Race*Region

Males, Females
18-24, 24-44, 45-46, 65+
White-non-Hispanic, Black-non Hispanic
Married, Previously Married, Never married,
None, GED/High School Diploma, Bachelor, Master/PHD
Poor, Near poor, Low income, Middle income, High income
Northeast, Midwest, South, West
Non-MSA, MSA
Uninsured, Dual Eligible, Medicaid, Medicare, Other public,
private only
White-Male, White-Female, Black-Male, Black-Female
White- 18 to 44, White 45 &more, Black 18 to 44, Black 45 &
more
White-Northeast, White-Midwest, White-South, White-West
Black-Northeast, Black-Midwest; Black-South, Black-West
White – Male- 18 to 44, White – Male- 45 & more
White – Female- 18 to 44, White – Female- 45 & more
Black – Male- 18 to 44, Black – Male- 45 & more
Black – Female- 18 to 44, Black – Female- 45 & more

Race/Ethnicity

Race*Gender
Rage*Age

Levelsa

Age

Gender
Age in years
Race/ethnicity
Marital Status
Education
Poverty Category
Region
MSA
Insurance Coverage

Gender

Sub-population

9

9
9

9
9
9

9
9
9
9

9
9
9
9
9

9
9
9
9
9
9

9
9
9
9
9
9
9

9
9
9
9
9
9
9
9

9
9
9
9
9
9
9
9

9
9
9
9
9
9
9
9

9
9
9
9
9
9
9

9
9
9
9
9
9

9
9
9
9
9

9
9
9
9

9
9
9

9
9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9

9
9
9

9

9

9

9

To estimate cost for each sub-population, sample includes individuals in that population only; PHS = Perceived Health Status; MSA
= Metropolitan /statistical Area, CCI = Charlson comorbidity Index; GED = Graduate Equivalency Degree.
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CHAPTER 4.

RESULTS

Results of the current research are provided in this chapter. The first section
provides descriptive statistics for the study population. In the second section, results of
estimating direct medical costs associated with anxiety disorders are presented. Morbidity
and mortality costs attributable to anxiety disorders are provided in third and fourth
sections, respectively. Finally, summary of results, i.e. societal cost of anxiety disorders,
is reported.
Throughout this chapter, all dollar amounts are presented in 2013 dollar values,
unless otherwise is specified
Descriptive Statistics
Prevalence of Self-reported Anxiety Disorders in MEPS
From the total survey respondents in 2009-2010 (n = 66,148), 46,572 (weighted
sum = 228,987,954) were adults with positive person weights and non-missing values on
all of the independent variables, and were included in the final analysis. In 2009-2010
MEPS survey, 8.74% (weighted sum = 20,337,553) of adults (95% CI: 8.32% to 9.17%)
reported being diagnosed with an anxiety disorder(s). The remaining 91.26% were
considered as anxiety-free population.
Characteristics of the Study Population
Table 4-1 compares demographic characteristics of individuals with and without
anxiety disorder(s) in the study population. Compared to adults with no anxiety disorder,
those who have been diagnosed with this condition were more likely to be female
(66.15% versus 50.15%; p < 0.001), White-non Hispanic (79.87% versus 66.77%; p <
0.001), in the age group of 45 to 64 (40.74% versus 34.19%; p < 0.001), and have one or
more comorbidities (36.48% versus 27.98%; p < 0.001). Alternatively, they were less
likely to lack insurance (15.30% versus 20.77%; p < 0.001). Also, the mean ± SE of CCI
score was significantly higher at 0.82 ± 0.03, for sufferers of anxiety, compared to adults
without anxiety disorders at 0.51 ± 0.01.
We also compared the two populations based on the 17 comorbidities used in the
D’Hoore adaptation of the CCI (Table 4-2). In comparison with the anxiety-free
population, adults with anxiety disorders were more likely to have congestive heart
failure (1.49% versus 0.94%; p = 0.004), peripheral vascular disease (1.96% versus
1.28%; p = 0.020), dementia (0.95% versus 0.53%; p = 0.034), chronic pulmonary
disease (16.02% versus 8.55%; p < 0.001), connective tissue disease (5.19% versus
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Table 4-1.

Comparison of demographic characteristics between adults with and without anxiety disorders.

Characteristics
Gender
male
female
Age in years
18-24
25-44
45-64
65 and Older
Race/ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic
Other non-Hispanic
Marital Status
Married
Previously Marriedb
Never Married
Education
No Degree
GED/High School Diploma
Bachelor
Master/PhD
Other Degree

Adults (unweighted n=47,388)a
Anxiety disorder(s)
No anxiety disorder
a
(unweighted n=3,610)
(unweighted n=43,778)a
%
95% CI
%
95% CI
33.85
66.15

32.10-35.59
64.41-67.90

49.85
50.15

p-value
< 0.001*

49.29-50.42
49.58-50.72
< 0.001*

8.61
34.30
40.74
16.35

7.18-10.30
31.76-36.84
38.55-42.94
14.58-18.13

13.22
34.97
34.19
17.61

12.65-13.79
33.97-35.98
33.32-35.07
16.74-18.49
< 0.001*

79.87
6.97
8.99
4.17

77.82-81.92
5.88-8.06
7.63-10.36
3.25-5.09

66.77
11.92
14.41
6.90

64.88-68.65
10.64-13.21
12.78-16.04
5.88-7.92
< 0.001*

47.02
29.49
23.48

44.36-49.68
27.19-31.80
21.17-25.79

53.80
19.13
27.07

52.70-54.91
18.29-19.96
26.24-27.90
< 0.001*

13.09
52.75
17.60
7.10
9.46

11.75-14.42
50.21-55.28
15.79-19.41
5.83-8.38
8.06-10.87
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15.88
48.45
18.10
9.41
8.16

15.09-16.67
47.50-49.40
17.27-18.94
8.71-10.12
7.68-8.63

Table 4-1.

(Continued).

Characteristics
Poverty Category
Poor
Near Poor
Low Income
Middle Income
High Income
Region
Northeast
Midwest
South
West
MSA
Non-MSA
MSA
Insurance Coverage
Uninsured
Dual eligiblec
Medicaid
Medicare
Other Public
Private
CCI Score [mean (SE)]
CCI Score (%)
Zero Comorbidity
One Comorbidity

Adults (unweighted n=47,388)a
Anxiety disorder(s)
No anxiety disorder
a
(unweighted n=3,610)
(unweighted n=43,778)a
%
95% CI
%
95% CI
16.53
4.07
13.35
32.09
33.96

14.87-18.20
3.24-4.89
11.78-14.93
30.18-34.00
31.33-36.58

12.18
4.37
13.47
30.25
39.73

p-value
< 0.001*

11.46-12.89
4.06-4.67
12.83-14.12
29.42-31.08
38.36-41.10
< 0.001*

18.34
25.54
31.38
24.74

15.74-20.95
23.15-27.94
28.55-34.20
22.42-27.06

18.48
21.41
37.14
22.97

17.06-19.91
20.11-22.71
35.42-38.87
21.44-24.49
0.901

16.00
84.00

12.62-19.38
80.62-87.38

15.85
84.15

13.35-18.35
81.65-86.66
< 0.001*

15.30
13.53-17.06
4.57
3.59-5.55
10.15
8.73-11.58
18.32
16.44-20.20
1.89
1.25-2.53
49.76
47.33-52.20
0.82 (0.03)

20.77
19.72-21.81
2.08
1.84-2.31
5.59
5.07-6.11
16.94
16.09-17.79
1.86
1.59-2.13
52.77
51.47-54.06
0.51(0.01)

63.52
23.93

72.02
20.18

61.39-65.66
22.08-25.78
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71.25-72.79
19.67-20.78

<0.001*
<0.001*

Table 4-1.

(Continued).

Characteristics
Two Comorbidity
Three or More

Adults (unweighted n=47,388)a
Anxiety disorder(s)
No anxiety disorder
a
(unweighted n=3,610)
(unweighted n=43,778)
%
95% CI
%
95% CI
8.74
7.56-9.92
5.63
5.29-5.97
3.81
3.02-4.60
2.17
1.95-2.39

p-value

Notes: Unweighted numbers represent number of individuals in the sample, while weighted numbers represent projected
number of individuals (i.e. national-level estimates), after controlling for the complex survey design of MEPS. CI =
Confidence Interval; GED = Graduation Equivalency Degree; MSA = Metropolitan Statistical Area; CCI = Charlson
Comorbidity Index; SE = Standard Error.
a
Sample estimates projected to 232,782,004 adults, among which 20,337,553 were classified as anxiety patients and the
remaining 212,444,451 were considered as anxiety-free population. b Previously married refers to divorced, separated or
widowed individuals. c Dual eligible refers to individuals who are entitled to Medicare Part A and/or Part B and also meet the
eligibility requirements for Medicaid, therefore are enrolled in both programs.
* p < 0.05, two-tailed.
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Table 4-2.

Comparison of CCI clinical conditions between anxiety and non-anxiety patients.

Comorbidities
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Dementia
Cerebrovascular disease
Chronic Pulmonary disease
Connective tissue disease
Ulcer disease
Mild liver disease
Hemiplegia
Moderate or severe renal disease
Diabetes
Any tumor
Leukemia
Lymphoma
Moderate or severe liver disease
Metastasis solid tumor

Adults (unweighted n=47,388)a
Anxiety disorder(s)
No anxiety disorder
a
(unweighted n=3,610)
(unweighted n=43,778)a
%
95% CI
%
95% CI
3.31 2.51-4.10
2.92
2.65-3.18
1.49 1.02-1.96
0.94
0.79-1.09
1.96 1.34.2.57
1.28
1.12-1.44
0.95 0.51-1.40
0.53
0.40-0.66
0.28 0.02-0.55
0.18
0.11-0.25
16.02 14.30-17.74
8.55
8.08-9.01
5.19 4.30-6.07
2.93
2.65-3.21
0.91 0.55-1.26
0.43
0.32-0.54
0.74 0.41-1.07
0.48
0.38-0.57
3.04 2.29-3.79
2.18
1.94-2.41
0.59 0.27-0.90
0.39
0.28-0.48
12.24 10.93-13.54
10.78
10.28-11.28
7.06 5.87-8.26
6.10
5.69-6.52
0.11 0.00-0.25
0.15
0.09-0.21
0.19 0.02-0.36
0.25
0.18-0.33
0.26 0.06-0.46
0.30
0.21-0.38
0.65 0.34-0.97
0.45
0.36-0.54

a

p-value
0.318
0.004*
0.020*
0.034*
0.381
<0.001*
<0.001*
0.002*
0.058
0.009*
0.163
0.032*
0.110
0.621
0.532
0.759
0.168

Sample estimates projected to 232,782,004 adults, among which 20,337,553 were classified as anxiety patients and the
remaining 212,444,451 were considered as anxiety-free population.
* p < 0.05, two-tailed.
Source: D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with
administrative data bases. J Clin Epidemiol. Dec 1996;49(12):1429-1433.
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2.93%; p < 0.001), ulcer disease (0.91% versus 0.43%; p = 0.002), hemiplegia (3.04%
versus 2.18%; p = 0.009), and diabetes (12.24% versus 10.78%; p = 0.032).
Direct Medical Costs Attributable to Anxiety Disorders
Preliminary Statistical Analyses
As it was mentioned in chapter 3, direct medical costs associated with anxiety
disorders were estimated using the incremental cost approach. In this regard, several
multivariate regression analysis were conducted to separately model overall healthcare
expenditure, inpatient visits expenditure, outpatient visits expenditure, emergency room
visits expenditure, prescription medications expenditure, office-based medical visits
expenditure, and other medical expenses. However, we first needed to find the set of
covariates for regression models, as well as the type of regression analyses used to model
healthcare cost data. As such, the following preliminary analyses were conducted.
Checking for multicollinearity. As it was mentioned in chapter 3, an initial set
of variables, based on the relevant literature and availability of data in MEPS, was
selected to be included in all regression analyses. However, in the presence of strong
multicollinearity between two or more covariates of a model, predictions may be biased.
In such cases, either some covariates should be excluded from the model, or those with
high collinearity should be combined into a new single index Variance Inflation Factor
(VIF) is highly being used by researchers to identify multicollinearity. VIF simply
measures how much a variable is contributing to the standard error in the regression. If
there is severe multicollinearity between two or more variables in a model, the variance
inflation factor will be very large for those variables. The general rule of thumb to
identify multicollinearity is to use the cut point of 10 for VIF.78 That is, if the VIF for a
particular variable is higher than 10, that variable should either be excluded from the
model or be combined with other variables with high VIFs. Some researchers though find
the cut point of 10 to be very conservative and instead go with lower cut points such as 3
or 4.78 The VIF cut point of 4 was selected in this study.
In order to find out if there is multicollinearity in our data, we run an OLS
regression and asked for the VIF to be displayed in the output. The results are shown in
Table 4-3. According to Table 4-3, the mean VIF for the set of covariates is equal to
2.03. Also; the majority of independent variables have VIFs less than 4. The only
variables with high VIFs are age 65 to 85 (VIF=7.48), and Medicare (VIF=5.71). It
means that there is possibly a high collinearity between these two variables (people 65
years and older are more likely to be enrolled in Medicare). However, we still can’t say
that there is a severe collinearity between these two variables, since neither of the VIFs
exceeds 10. Also, we cannot eliminate any of these two variables since they are all
specific levels of other categorical variables (age and insurance). Finally, insurance
coverage and age are shown to have significant impact on healthcare cost.79-83 Taking all
these into account and after consulting with the biostatistician expert of the project,
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Table 4-3.

Results of regression analysis to check for multicollinearity.

Variable
No anxiety disordera
Anxiety disorders
Malea
Female
Age 18 to 24a
Age 25 to 44
Age 45 to 64
Age 65 and more
Whitea
Black
Hispanic
Other
Marrieda
Previously married
Never married
No Degreea
GED/high school diploma
Bachelor
Master/PhD
Other degree
Poora
Near poor

VIF

Variable

VIF

a

Poor
Low income
Middle Income
High income
Uninsureda
Dual eligible
Medicaid
Medicare
Other public insurances
Private insurance only
Northeasta
Midwest
South
West
Non MSAa
MSA
Excellent PHSa
Very good PHS
Good PHS
Fair PHS
Poor PHS
Charlson Comprbidity Index

1.06
1.05
3.09
3.67
7.48
1.32
1.57
1.18
1.27
1.73
1.90
1.87
1.53
1.37
1.27

Note: Mean VIF = 2.03.
a
Reference Category.
VIF = Variance Inflation Factor.
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1.70
2.39
2.87
1.72
1.34
5.71
1.08
2.01
1.88
2.23
2.08
1.09
1.63
1.72
1.56
1.30
1.34

we decided to keep all covariates in the model.
Finding the distribution of cost data. In modeling healthcare cost data, the
specific distributional characteristics of the data must be taken into consideration. These
characteristics are: (1) non-negative observations; (2) excessive zero (i.e. there are a large
number of individuals with zero cost); and (3) highly skewed data (i.e. the majority of
cost is incurred by a few patients).68 These characteristics make traditional Ordinary
Least Square (OLS) regression inefficient in modeling healthcare cost data. Figure 4-1
shows the distribution of overall healthcare cost for the study population. As it was
expected, healthcare cost data is highly skewed. So, OLS regression could not be used to
model this type of data.
Alternatively, OLS with natural log-transformed cost data has been widely used to
deal with heavily skewed data. However, this approach has some limitations as well.68
First, the outcome variable is the logarithm of cost. So in order to draw useful
conclusions about the cost, the predicted values need to be retransformed back to the
original scale. While retransforming the outcome variable, by using smearing factor,
seems straightforward, interpretation of parameter estimates may still be challenging.
Second, in the presence of heteroskedasticity, using one smearing factor to retransform
the predicted values leads to biased estimates, i.e. under-estimation or over-estimation of
the actual cost. Figure 4-2 depicts the distribution of the log-transformed overall cost for
the study population. As it is shown in this figure, log-normal distribution is a perfect fit
to our data and therefore, OLS with log-transformed cost data seems to be an appropriate
regression model. However, we still needed to check for heteroskedasticity in logtransformed data. Table 4-4 shows the result of Breusch-Pagan / Cook-Weisberg test for
heteroskedasticity. According to this result, error terms have non-constants standard
deviation. In other forms, heteroskedasticity is present with log-transformed data. So,
OLS regression with log-transformed cost data was also ruled out.
In such scenarios, a Generalized Linear Model (GLM), with appropriate variance
and link functions, is more efficient to model cost data. GLM directly models both the
variance and mean functions on the original scale of dependent variable. As such, results
can be interpreted with no need for retransformation from log scale to the original scale.68
The link function generally used with healthcare cost data is the log-link function.68
In order to identify the appropriate variance function, a Park test was conducted.
Result of this test, which is shown in Table 4-5, suggested that both Poisson and Gamma
variance function might be appropriate for our data. We modeled overall healthcare cost
data once using log-link GLM with Poisson distribution and then with log-link GLM with
Gamma distribution These two models were compared based on (1) correlation between
the predicted and observed expenditures (to see how well predictions of each model
matched the observed data), and (2) mean squared error (as a summary of overall
goodness of fit for each model). The comparison is shown in Table 4-6. Finally, a loglink GLM with Poisson distribution was selected as the best fitting model for modeling
the overall healthcare expenditure, as well as all categories of expenditure.
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Figure 4-1.

Distribution of the overall healthcare cost for the study population.

Mu = Mean, Sigma = Standard Deviation.
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Figure 4-2. Distribution of the log-transformed overall healthcare cost for the
study population.
Mu= Mean, Sigma=Standard Deviation, totlog=log-transformed overall cost.
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Table 4-4.
Results of the Breusch-Pagan/Cook-Weisberg test for
heteroskedasticity.
Variable
totlog

Chi-square
360.07

P-value
< 0.0001*

Note: The null hypothesis in the Breusch-Pagan / Cook-Weisberg test is that all error
terms have constant variance. Since the P-value is less than 0.05, we reject the null
hypothesis. In other words, heteroskedasticity is present.
totlog = log-transformed overall cost.

Table 4-5.

Results of Park test.

Parameter estimate (λ)
1.64

SE
0.01

95% CI
1.61-1.66

p-value
< 0.0001*

Note: Since the parameter estimate for the λ is between 1 and 2, it means that both
Poisson variance function (λ=1), and Gamma variance function (λ=2) could be
appropriate candidates.
SE = Standard Error, CI = Confidence interval.
* p < 0.05, two-tailed.

Table 4-6.
Variance
function
Poisson
Gamma

Comparison of Poisson and Gamma variance functions.
Correlation between predicted
and observed values
0.39
0.34
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Mean square error
(MSE)
1.19e+08
2.07e+08

After deciding on the best fitting regression model, several multivariate regression
analyses were conducted to separately model overall healthcare expenditure, inpatient
visits expenditure, outpatient visits expenditure, emergency room visits expenditure,
prescription medications expenditure, office-based medical visits expenditure, and other
medical expenses. Results are provided in the following sections.
Overall Incremental Direct Medical Expenditure Attributable to Anxiety Disorders
Table 4-7 shows the result of regression analysis to estimate the overall
incremental direct medical expenditure attributable to anxiety disorders. After controlling
for gender, age, race/ethnicity, marital status, education, poverty category, geographic
region, MSA, PHS, health insurance coverage, and the CCI, adults with anxiety disorders
had 33% higher overall medical expenditure than those without anxiety disorders
(parameter estimate: 1.33; p < 0.001). The adjusted annual overall incremental medical
expenditure associated with anxiety disorders was estimated at $1657.52 per person (SE:
$238.83; p < 0.001).The total annual incremental direct medical expenditures attributable
to anxiety disorders, for the U.S. ambulatory adult population, is at $33.71 billion in 2013
US dollars. This figure was obtained by multiplying the per-capita incremental cost of
anxiety ($1657.52) by the national estimated prevalence of anxiety disorders in MEPS
(20.34 million persons).
Incremental Direct Medical Expenditure by Health Delivery Setting (SA2)
Results from individual regression models of the incremental expenditure
attributable to anxiety disorders, by service category, are described in Table 4-8. The
adjusted annual incremental medical expenditure associated with anxiety disorders by
health service category are as follow: Inpatient care, estimated at $567.83 (SE: 176.65, p
= 0.001) accounted for the largest proportion of the overall medical expenditures.
Prescription medications at $531.83 (SE: 64.34; p < 0.001) accounted for the second
largest proportion of the overall expenditures, followed by office-based medical provider
visits at $362.41(SE: 79.58, p < 0.001). Although statistically significant, emergency
room visits and other medical expenses together explained less than 8% of the overall
medical expenditure. These cost categories were estimated at $37.02 (SE: 18.28; p =
0.043) and $80.85 (SE: 38.87, p = 0.038), respectively. Cost of outpatient visits estimated
at $42.52 (SE: 54.69; p = 0.437), was not statistically significant.
Incremental Direct Medical Expenditure for Different Sub-populations (SA3)
In order to estimate the incremental direct medical expenditures associated with
anxiety disorders for different sub-populations (based on gender, age, race/ethnicity,
marital status, education, poverty category, region, MSA, and insurance coverage),
separate multivariate regression analyses (GLM with Poisson distribution and log-link
function) were conducted. To estimate the costs in each sub-population, the regression
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Table 4-7.
Results of regression analysis to estimate the overall incremental
direct medical expenditure associated with anxiety disorders.
Parameter
No anxiety disorderb
Anxiety disorders
Maleb
Female
Age 18 to 24b
Age 25 to 44
Age 45 to 64
Age 65 and Older
Whiteb
Black
Hispanic
Other
Marriedb
Previously
marriedc
Never married
No Degreeb
GED/high school
diploma
Bachelor
Master/PhD
Other degree
Poorb
Near poor
Low income
Middle Income
High income
Uninsuredb
Dual eligibled
Medicaid
Medicare
Other public
Private
Northeastb
Midwest
South
West

Parameter
estimate

SE

1.33

0.05

1.24-1.43

< 0.001

1.17

0.03

1.11-1.24

< 0.001

1.08
1.51
1.33

0.06
0.09
0.11

0.97-1.21
1.34-1.71
1.13-1.57

0.174
< 0.001
0.001

0.94
0.74
0.71

0.04
0.03
0.04

0.88-1.02
0.68-.80
0.64-0.78

0.113
< 0.001
< 0.001

0.99

0.03

0.93-1.06

0.873

0.91

0.04

0.84-0.98

0.016

1.17

0.05

1.07-1.27

0.001

1.39
1.42
1.25

0.08
0.09
0.08

1.25-1.55
1.26-1.61
1.11-1.41

< 0.001
< 0.001
< 0.001

0.93
1.02
1.02
1.16

0.05
0.05
0.05
0.06

0.83-1.05
0.93-1.12
0.93-1.12
1.04-1.30

0.238
0.689
0.687
0.006

3.63
2.28
2.92
2.10
1.93

0.35
0.17
0.23
0.18
0.12

3.00-4.40
1.97-2.63
2.50-3.41
1.77-2.50
1.71-2.17

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

1.04
0.94
0.99

0.05
0.04
0.04

0.96-1.14
0.86-1.02
0.91-1.08

0.345
0.136
0.759
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95% CI

p-value

Table 4-7.

(Continued).

Parameter
Non MSAb
MSA
Excellent PHSb
Very good PHS
Good PHS
Fair PHS
Poor PHS
CCI
Intercept

Parameter
estimate

SE

1.14

0.04

1.36
2.02
3.12
4.50
1.19
627.05

0.06
0.09
0.18
0.32
0.01
63.76

95% CI

p-value

1.06-1.23

0.001

1.25-1.49
1.86-2.20
2.78-3.51
3.91-5.18
1.17-1.21
513.14-766.24

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

Notes: Results are based on generalized linear model with log-link function and Poisson
distribution. Unweighted number of individuals = 46,572.
SE = Standard Error; CI = Confidence Interval; GED= Graduation Equivalency Degree;
MSA = Metropolitan Statistical Area; PHS= Perceived Health Status; CCI = Charlson
Comorbidity Index.
a
Sample estimates projected to 228,987,954 adults with positive person weights and nonmissing values on all of the independent variables; b Reference Category; c Previously
married refers to divorced, widowed, or separated individuals; d Dual eligible refers to
individuals who are entitled to Medicare Part A and/or Part B and also meet the eligibility
requirements for Medicaid, therefore are enrolled in both programs.

Table 4-8.
Results of regression analyses to estimate the incremental
expenditures of anxiety disorders by service category.
Service category

AIC ($)

SE

Inpatient visits
Outpatient visits
Office-based visits
Emergency room visits
Prescription medications
Other medical expenses
Overall expenditure

567.83
42.52
362.41
37.02
531.83
80.85
1657.52

176.65
54.69
79.58
18.28
64.34
38.87
238.83

p-value

Total costa

%b

0.001
0.437
<0.001
0.043
<0.001
0.038
<0.001

$11.55 B
$864.75 M
$7.37 B
$752.90 M
$10.82 B
$1.64 M
$33.71 B

35.00%
2.62%
22.34%
2.28%
32.78%
4.98%
100.00%

Note: All costs are presented in 2013 US dollars.
AIC = Average Incremental Cost; SE = Standard Error; B = Billion; M = Million.
a
Calculated by multiplying the average incremental cost by the prevalence of anxiety
disorders in MEPS (i.e. 20.34 million persons). b Percent of overall expenditure.
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analysis was conducted on that sub-population only and therefore, the covariate
identifying that sub-population was excluded from the regression model. For instance, to
estimate the incremental cost of anxiety disorders among males, the regression analysis
was conducted on males, excluding gender from covariates of the model. Results are
provided in Table 4-9.
According to these findings, having anxiety disorder(s) leads to statistically
significant increase in direct medical expenditures almost for all sub-populations. The
only exceptions are Hispanics, individuals with education levels lower than GED, and
those who are uninsured, have Medicaid, or other public insurances (such as VA,
Tricare,…). The highest increases in direct medical costs as a result of anxiety disorder(s)
were seen in the following sub-populations: dual-eligible, those who live in non-MSA
regions, highly educated individuals (with Master or PhD degree), seniors (65 years of
age and older), Medicare enrollees, Midwest residents, divorced, widowed, or separated
individuals, females, people with middle income, and Whites (non-Hispanic).
We have looked at the cost of anxiety disorders among Blacks and Whites (but
not Hispanics, since presence of anxiety disorders did not have a statistically significant
impact on healthcare cost of this population) even further. More specifically, we broke
down each of these race/ethnicity categories, by age, gender and geographic region. The
totals of 24 separate multivariate regression analyses were conducted to estimate cost of
anxiety disorders in each of these groups. Results are provided in Table 4-10. According
to these results, for both race/ethnicity groups (White non-Hispanics and Black nonHispanics) females and individuals 45 years and older accounted for the majority of cost.
This is the exact same observation we had when looking at the costs of all race/ethnicities
together.
Regarding geographic region, we found that geographic variations did not impact
cost of anxiety disorders among White non-Hispanics. In fact, in all geographic regions,
anxiety disorders led to statistically significance increase in direct medical expenditures
among White non-Hispanics. More specifically, White non-Hispanics who reside in
Midwest had higher costs (similar to what we had already found for all race/ethnicities
combined). However, Blacks had different cost pattern. In fact, among Black nonHispanics, only those who reside in northeast had higher medical costs due to anxiety
disorders and for other geographic regions, anxiety related costs were not statistically
significant. It should be further investigated to see whether prevalence of anxiety
disorders is higher among Blacks in northeast, or the zero cost of anxiety disorders for
people of color, who reside in other regions, is due to some barrier in receiving the
required care.
These findings all demonstrate why it is important to calculate values for
subgroups. If we just looked at the incremental costs for men among Whites and Blacks,
it looks like the costs are very similar ($1213.60 and. $1216.57) (Table 4-10). However,
looking at the age segments, we saw that the costs for White non-Hispanic males were
similar between age groups ($1172.83 and $1116.29), but they were incredibly different
for Black non-Hispanic males, where older Black males had an incremental cost nearly
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Table 4-9.
Incremental direct medical expenditures associated with anxiety
disorders for different sub-populations.
Sub-population
Gender
Male
Female
Age in years
18-24
25-44
45-64
65 and more
Race/ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic
Marital Status
Married
Previously Marrieda
Never Married
Education
None
GED/High School
Diploma
Bachelor
Master/PHD
Poverty Category
Poor
Near Poor
Low Income
Middle Income
High Income
Region
Northeast
Midwest
South
West
MSA
Non-MSA
Insurance Coverage
Uninsured

Adjusted mean
incremental cost ($)

SE

963.97
2137.98

342.64
330.96

0.005*
< 0.001*

1498.39
771.47
2102.74
2426.40

439.97
281.03
432.29
765.072

0.001*
0.006*
< 0.001*
0.002*

1879.31
1459.30
472.98

310.15
671.15
344.68

< 0.001*
0.030*
0.170

1522.56
2305.23
1814.21

370.62
588.36
393.55

< 0.001*
< 0.001*
< 0.001*

1069.70

560.54

0.056

1795.34

324.47

< 0.001*

1615.17
2463.31

552.84
1058.67

0.003*
0.020*

1710.80
1594.02
1087.15
2048.08
1469.45

555.70
1089.02
601.07
423.33
473.18

0.002*
0.143
0.070
< 0.001*
0.002*

1463.21
2338.59
1197.91
1718.05

495.22
572.02
364.88
421.48

0.003*
< 0.001*
0.001*
< 0.001*

2485.64

621.19

< 0.001*

483.63

313.77

0.123
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p-value

Table 4-9.

(Continued).

Sub-population
Dual Eligibleb
Medicaid
Medicare
Other Public
Private Only

Adjusted mean
incremental cost ($)
6455.84
1129.83
2354.90
781.37
1571.62

SE
1990.81
769.44
778.10
891.45
319.97

p-value
0.001*
0.142
0.002*
0.381
< 0.001*

Note: All costs are presented in 2013 US dollars.
a
Previously married refers to divorced, widowed, or separated individuals. b Dual eligible
refers to individuals who are entitled to Medicare Part A and/or Part B and also meet the
eligibility requirements for Medicaid, therefore are enrolled in both programs.
SE = Standard Error; GED= Graduation Equivalency Degree; MSA = Metropolitan
Statistical Area.
* p < 0.05, two-tailed
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Table 4-10. Breaking down the cost of anxiety disorders among different
race/ethnicities by gender, age, and geographic region.
Sub-population
Gender
Male
Female
Agea
18-44
45 and over
Region
Northeast
Midwest
South
West
Gender - Age
Male - 18 to 44
Male - 45 and over
Female - 18 to 44
Female - 45 and over

Incremental direct medial cost (SE)
White non-Hispanic Black non-Hispanic
1213.60 (475.32)*
2318.78 (424.48)*

1216.57 (920.13)
1797.20 (865.29)*

1060.49 (307.34)*
2431.47 (497.92) *

1268.23 (803.82)
2189.18 (995.05) *

1406.38. (532.84) *
2071.76 (600.52) *
1413.00 (435.31) *
1478.93 (450.03) *

3899.40 (1890.84) *
824.05 (1054.74)
491.19 (645.86)
2001.25 (1459.93)

1172.83 (444.11) *
1116.29 (738.16)
1235.21 (456.88) *
3150.09 (696.68) *

650.61 (417.22)
3932.22 (1767.89) *
2315.74 (1277.64)
1843.72 (1314.72)

Note: All costs are presented in 2013 U.S. dollars; Results are not provided for the
Hispanics, since presence of anxiety disorder(s) did not have a statistically significant
impact on healthcare cost of this population.
a
Age groups were combined to get enough sample size in each cell.
SE = Standard Error.
* p < 0.05, two-tailed.
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six times that of the 18-44 year old ($3932.22 and $650.61). For women, we saw a
difference in the costs by age group, but older White women had a higher cost (nearly as
much as older Black men) and for Black women we saw higher cost is in the younger age
group. So, there is a need for future studies to figure out why all of these incremental
costs vary so much.
Morbidity Cost Associated with Anxiety Disorders
As it was mentioned in the third chapter, morbidity cost was measured using the
Human Capital Approach (HCA). In the HCA, productivity loss due to an illness or
injury is approximated by valuing the entire period of absence from work by average
individual’s earning. For individuals who are at paid employment for at least one round
in the year, information on wage rates are available in the MEPS (in both Consolidated
Data file and Job file). For unemployed individuals, the period in which they had to stay
in bed due to an illness or injury is valued by the average wage for private household
services. Equation 4-1 shows the formula to calculate the morbidity cost.
Morbidity Cost ൌ ൬
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(Eq. 4-1)

Where:
N = Total number of individuals in the sample.
Wti = Person weight for the ith individual in the sample.
Wgi = Daily wage for employed individuals and average daily wage for household
services if the individual is not employed.
ni = Number of missed work days (due to anxiety disorders) for employed individuals and
number of days stayed in bed (due to anxiety disorders) for unemployed individuals.
Nanx = Weighted number of individuals in the sample with anxiety disorder(s).
Number of Missed Work Days due to Anxiety Disorders for Employed Individuals
Since MEPS reports the total number of missed work days for each individual
(due to all medical conditions he/she might have), we needed to find the incremental
number of missed work days specifically due to anxiety disorders. A multivariate
regression analysis was conducted (the very same approach we used to estimate the
incremental direct medical costs). The outcome variable was the total number of missed
work days and the covariates were gender, age, race/ethnicity, marital status, education,
geographic region, MSA, Charlson comorbidity index, occupation category, union status,
number of employees, and sick pay (whether or not the person has the sick pay benefit).
Checking for multicollinearity. Table 4-11 shows the results of
multicollinearity analysis. VIF for insurance coverage and poverty category were
estimated at 5.78 and 4.91 respectively. Since both of these values exceeded the cut point
of 4, and also there is no evidence in the literature supporting the impact of these
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Table 4-11.

Results of multicollinearity analysis for modeling the number of missed work days.

Variable

VIF
a

No anxiety disorder
Anxiety disorders
Malea
Female
Age 18 to 24a
Age 25 to 44
Age 45 to 64
Age 65 to 85
Whitea
Black
Hispanic
Other
Marrieda
Previously married
Never married
No Degreea
GED/high school diploma
Bachelor
Master/PhD
Other degree

1.03
1.22
3.53
3.97
1.44
1.24
1.30
1.12
1.19
1.46
3.08
3.03
2.35
1.95

Variable
Management, business, and financial operations
Professional and related occupations
Service Occupations
Sales and related occupations
Office and administrative support
Farming, fishing, forestry
Construction. Extraction, and maintenance
Production, transportation
Sick-pay benefita
No sick-pay benefit
Uniona
Non-union
Number of employees
Northeasta
Midwest
South
West
Non MSAa
MSA
Charlson Comprbidity Index

Note: Mean VIF = 1.85.
a
Reference Category.
VIF = Variance Inflation Factor.
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VIF
a

2.31
2.37
1.75
2.11
1.14
1.64
2.06
1.34
1.13
1.11
2.10
2.35
2.14
1.06
1.08

variables on the number of missed work days,72 they were excluded from the model.
There is no multicollinearity with the remaining set of covariates.
Finding the distribution of missed work days. Figure 4-3 shows the
distribution of number of missed work days (“wkinbd” variable in the MEPS data file).
Since the “wkinbd” had a highly-skewed distribution, use of OLS regression would have
led to biased estimates. So, OLS with log-transformed data and GLM regression were
considered. OLS with log-transformed data was ruled out; due to the heteroskedasticity in
data (result of the test for heteroskedasticity is provided in Table 4-12). Therefore, we
conducted the park test to identify the best variance function to be used in the GLM
regression (Table 4-13).
According to the results of Park test, both Poisson and Gamma variance functions
were appropriate fit to our data. We conducted a. log-link GLM with Poisson distribution
(to be consistent with the methodology used in estimating the direct medical costs), on
the employed individuals 18 years and older. Self-employed individuals were not
included in the analysis since information such as sick leave is not provided for them in
the MEPS. Table 4-14 shows the result of regression analysis to estimate the incremental
number of days missed work due to anxiety disorders. Based on these results, having
anxiety disorder(s) has increased the number of missed work days by almost 2.5 days.
Number of Days Stayed in Bed due to Anxiety Disorders for Unemployed
Individuals
For unemployed individuals, MEPS collects the total number of days each
individual had to stay in bed (due to all medical conditions he/she might have had during
the survey year). The variable representing this information in the MEPS consolidated
data file is called “ddbdys”.we needed to find the incremental number of bed days
specifically due to anxiety disorders. Distributional characteristics of the variable
“ddbdys” were pretty the same as they were for the variable “wkinbd”. In other words,
“ddbdys” was also highly skewed and error terms from the OLS regression on logtransformed “ddbdys” were also heteroskedastic. So, we conducted a log-link GLM with
Poisson distribution on the unemployed individuals in the sample to estimate the
incremental number of bed days due to anxiety disorder (s). The dependent variable in
the regression model was “ddbdys” and independent variables were gender, age,
race/ethnicity, education, marital status, geographic region, MSA, and Charlson
comorbidity index. Poverty category and insurance coverage were excluded from the set
of covariates due to their high multicollinearity with other variables (high VIF).
Table 4-15 shows the result of regression analysis to estimate number of bed days due to
anxiety disorders for unemployed individuals. As one can see, having anxiety disorders
has increased the number of bed days by more than 12 days, for unemployed individuals.
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Figure 4-3.
individuals.

Distribution of the number of missed work days for employed

WKINBD = Number of missed work days.
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Table 4-12. Results of the Breusch-Pagan/Cook-Weisberg test for
heteroskedasticity.
Variable
wkinbd_log

Chi-square
218.33

p-value
< 0.0001*

Note: The null hypothesis in the Breusch-Pagan / Cook-Weisberg test is that all error
terms have constant variance. Since the P-value is less than 0.05, we reject the null
hypothesis. In other words, heteroskedasticity is present.
wkinbd_log = log-transformed missed work days.

Table 4-13.

Results of Park test.

Parameter estimate (λ)
1.90

SE
0.04

95% CI
182-1.98

p-value
< 0.0001*

Note: Since the parameter estimate for the λ is between 1 and 2, it means that both
Poisson variance function (λ=1), and Gamma variance function (λ=2) could be
appropriate candidates.
SE = Standard Error, CI = Confidence interval.
* p < 0.05, two-tailed.

Table 4-14.

Incremental number of missed work days due to anxiety disorders.

Incremental estimate
2.18

SE
0.57

95% CI
1.05,3.30

p-value
< 0.0001*

SE = Standard Error, CI = Confidence interval.
* p < 0.05, two-tailed.

Table 4-15.

Incremental number of bed days due to anxiety disorders.

Incremental estimate
12.55

SE
1.62

95% CI
9.38,15.72

SE = Standard Error, CI = Confidence Interval.
* p < 0.05, two-tailed.
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p-value
< 0.0001*

Daily Wage for Employed Individuals
For individuals who were employed for at least one round during the survey year,
MEPS collects information on hourly wages, as well as the number of hours a person
works during a week. To convert hourly wages to daily wages, we assumed that each
individual worked 5 days a week. So, daily wage for employed individuals was
calculated according to the Equation 4-2.
DW= hours worked per day* HW = (hours worked per week/5) * HW

(Eq. 4-2)

Where:
DW = Daily wage.
HW = Hourly wage as it comes in the MEPS consolidated data file.
Average Daily Wage of Household Services for Unemployed Individuals
As it was mentioned in the chapter 3, in the HCA, morbidity cost for unemployed
individuals is calculated by valuing the time period in which an individual had to stay in
bed, due to an illness or injury (bed days).the assumption is that daily wage for
unemployed individuals is equal to the daily wage for services usually being done at
home (household services). For each survey year (2009 and 2010), we used the average
daily wage for cooks, maids and maintenance services, as the average daily wage for
household services. Results are provided in Table 4-16.
Summary of Analyses
Having all the information required to calculate the morbidity cost attributed to
anxiety disorders (according to Equation 4-1), summary of results are provided in Table
4-17. The adjusted mean incremental morbidity cost due to anxiety disorders was
estimated at $625.73 in 2013 US dollars. Multiplying this figure by the weighted number
of individuals with anxiety disorder(s) in this period (i.e. 20,337,553 adults), the total
morbidity cost associated with this category of mental illnesses was estimated at $12.72
billion in 2013 US dollars.
Mortality Costs Associated with Anxiety Disorders
As it was already defined in the chapter 3, mortality cost is productivity loss due
to premature deaths. In the HCA, mortality cost is the present value of future earnings,
from age of death to life expectancy. In this regard, mortality cost in HCA is calculated
using the formula in Equation 4-3.

 ܥܶܯൌ σ
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(Eq. 4-3)

Table 4-16.

Gender
Men

Women

Average daily wage for unemployed individuals based on BLS data.

Service category
Cook
Maid
Maintenance
Average
Cook
Maid
Maintenance
Average

Weekly wage ($)a
2009
2010
400
401
444
455
488
493
444
450
371
381
371
376
388
391
377
383

Daily wage ($)b
2009
2010

97

96

82

82

Note: Wage data for specific service categories is not available by further details such as
race/ethnicity.
a
In the current dollar value; b In 2013 dollar value.

Table 4-17.
Cost
Average
Total

Summary of results: Morbidity cost.
Adjusted incremental
SE
95% CI
p-value
estimate ($)
625.73
7.40 611.14,640.32
< 0.0001*
625.37*20,337,553= $12.72 billion in 2013 US dollars

SE = Standard Error, CI = Confidence interval.
* p < 0.05, two-tailed.

65

Where:
MTC = Mortality cost for individuals who committed suicide due to anxiety disorders in
the period of study.
Ad= Age of death.
Le= Life expectancy at age of death by race/ethnicity and gender.
Li= Labor force participation rate by gender and race/ethnicity at age i.
W= Average annual wage by gender and race/ethnicity at age of death.
Discount rate is equal to 3%.

Number of People Who Committed Suicide due to Anxiety Disorders and Age at
Death
NVSS provides number of deaths by age group, gender, Hispanic origin, and race
for non-Hispanic origin for different causes of death. These statistics are reported in
several different formats, based on the age group (5-year age group or 10-year age group)
and causes of death (for 15 major causes of death or for 113 causes of death).56-58 We
started collecting the number of deaths due to suicides for 2010, using the number of
deaths provided by 15 major causes of death in 5-year age groups, by Hispanic origin,
race for non-Hispanic population and sex. However, if for some specific sub-populations
suicide did not appeared in the first 15 causes of death, we had to use other data tables to
collect as much information as possible. Number of deaths due to suicide by age, gender,
and race/ethnicity are provided in Table 4-18. You may see that for some subpopulations the number of suicides is provided for 5-year age groups and for others in 10year age group. Since we had the number of deaths for each age group but not at each
specific age, we assumed that all deaths in each age group (either 5 or 10 year age
groups) have occurred in the middle point of that range. For instance, we assumed that
for all deaths between the ages of 20 to 25, the age at death was 22. In the same way, we
assumed that for all deaths occurred between the ages 65 to 75, the age at death was 70.
It has been shown that 10% of suicides are due to anxiety disorders.5,10 So, to get
the number of suicide due to anxiety disorders at certain age by gender and race/ethnicity,
we multiplied the figures in Table 4-18 by 10%.
Life Expectancy at Age of Death by Race/Ethnicity and Gender
NVSS also provides statistics on life expectancy at age of death by race/ethnicity
and gender.59 This information is provided in Table 4-19. If the age at death was a
multiplication of 10 (for 10-year age group), then we already have the life expectancy at
that age. However, for 5-year age groups (for instance 20 to 25), the life expectancy at
the age of death (22) is equal to the mean of life expectancies at the beginning (20) and
end (25) of that range.
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Table 4-18.

Number of suicides in 2010 by age, gender, and race/ethnicity.
White

Age
group
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85+
Total

Male
n
1,717
1,822
1,658
1,887
2,213
2,928
2,996
2,549
1,806
1,210
972
878
761
791

%
84%
82%
79%
77%
76%
77%
76%
76%
76%
79%
84%
47%
40%
88%

24,188

79%

Black
Female
n
%
335
16%
410
18%
445
21%
567
23%
692
24%
878
23%
953
24%
821
24%
558
24%
322
21%
179
16%

Male
n
259
239
186
180
160
140
119
97
70

%
84%
85%
88%
79%
77%
80%
76%
48%
34%
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Hispanic
Female
n
%
49
16%
43
15%
26
12%
47
21%
48
23%
36
20%
37
24%
36

18%

94%

4

6%

Male
n
307
272
232
211
196
197
150
138
67
57
40

%
82%
84%
88%
78%
83%
82%
82%
83%
78%
78%
78%

Female
n
%
18%
68
16%
51
12%
33
22%
59
17%
39
18%
42
18%
33
17%
29
22%
19
22%
16
22%
11

246

13%

38

79%

10

21%

59

89%

7

11%

110

12%

9

75%

3

25%

29

97%

1

6,516

21%

1,563

82%

339

18%

1,955

83%

408

3%
17%

Sources: Deaths, percent of total deaths, and death rates for the 15 leading causes of death in 10-year age groups, by Hispanic origin,
race for non-Hispanic population and sex: United States, 2010. Mortality Tables 2012;
http://www.cdc.gov/nchs/nvss/mortality_tables.htm. Accessed 11/25/2012 ; Deaths, percent of total deaths, and death rates for the 15
leading causes of death in 5-year age groups, by Hispanic origin, race for non-Hispanic population and sex: United States, 2010.
Mortality Tables 2012; http://www.cdc.gov/nchs/nvss/mortality_tables.htm. Accessed 11/25/2012; Deaths, percent of total deaths and
rank order for 113 selected causes of death and Enterocolitis due to Clostridium difficile, by Hispanic origin, race for non-Hispanic
origin and sex, United States, 2010, Mortality Tables 2012.
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Table 4-19. Life expectancy at selected ages by race, Hispanic origin, race for nonHispanic population, and sex: United States, 2010.
White nonHispanic

Hispanic
Age at
death
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100

Black nonHispanic

Male

Female

Male

Female

Male

Female

59.3
54.6
49.8
45.1
40.4
35.7
31.2
26.6
22.8
18.8
15.1
11.7
8.7
6.1
4.2
2.9
2.1

64.4
59.5
54.6
49.7
44.8
40.0
35.3
30.8
26.3
22.0
18.0
14.1
10.7
7.7
5.4
3.7
2.6

57.2
52.5
47.9
43.2
38.6
34.0
29.7
25.5
21.5
17.7
14.2
11.0
8.1
5.8
4.0
2.8
2.1

61.1
56.9
52.0
47.2
42.5
37.8
33.2
28.8
24.4
20.3
16.4
12.8
9.6
6.9
4.8
3.3
2.3

52.9
48.4
43.9
39.4
34.9
30.5
26.3
22.5
19.0
15.8
12.8
10.1
7.8
5.9
4.4
3.3
2.6

58.8
54.0
49.2
44.5
39.8
35.3
31.0
26.8
22.9
19.1
15.7
12.5
9.6
7.1
5.2
3.8
2.8

Source: Murphy SL, Xu JQ, Kochanek KD. Deaths: Final Data for 2010. National Vital
Statistics Reports. Hyattsville, MD: National Center for Health Statistics;2013.
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Labor Force Participation Rate and Wage
We collected information on LFPR and wage from the BLS.52,53 This information
is provided in Tables 4-20 and 4-21 respectively. In BLS, wage data are available only
for age groups of 16-24, 25-54, and 55+. So, we could not break down the wage data into
finer age groups.
Summary of Analyses
Having all the information required to calculate mortality cost according to
Equation 4-3, results of this section are provided in Table 4-22. Assuming that 10% of
suicides are due to anxiety disorders, 3,497 individuals committed suicide in 2010, with
anxiety disorder(s) as primary reason. This resulted in $2.34 billion (in 2013 US dollars)
loss in terms of mortality cost. White-non Hispanics accounted for almost 90% of this
figure, mainly because of significantly higher number of suicides in this sub-population.
Among White-non Hispanics, males between the ages of 25 and 44 years, had the highest
mortality cost (37.71% of total mortality cost).
The Societal Cost of Anxiety Disorders for the U.S. Adult Population in 2010 (SA1)
The societal cost of anxiety disorders was estimated, by adding-up the overall
direct medical cost, morbidity cost, and mortality cost, at almost $49 billion in 2013 US
dollars. Direct medical cost accounted for the majority of this figure (69.12%), followed
by morbidity cost at 26.08% and mortality cost at 4.81%. These results are provided in
Table 4-23.
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Table 4-20.

Labor force participation rate by age, gender, and race/ethnicity.
White non-Hispanic

Age
group
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75+

Black non-Hispanic

Hispanic

Men

Women

Men

Women

Men

Women

77.0
90.0
92.3
93.3
91.6
89.7
86.5
79.7
61.3
37.2
22.5
10.5

69.7
76.2
73.6
73.7
76.2
77.2
75.3
69.4
51.7
27.6
15.0
5.3

66.9
82.3
84.7
86.8
85.5
79.6
75.1
65.2
46.7
27.9
16.3
9.3

66.9
76.7
79.3
78.2
77.1
75.3
70.6
63.6
44.2
24.2
13.0
5.6

80.0
91.9
93.5
94.1
91.5
88.6
86.7
77.1
57.8
38.7
23.4
10.9

61.6
67.7
64.9
66.7
69.3
72.2
67.7
60.5
44.5
24.3
10.4
5.5

Source: Labor Force Statistics from the Current Population Survey. Bureau of Labor
Statistics. http://bls.gov/data/. Accessed 11/05/2012.

Table 4-21. Median usual weekly earnings in current dollar from current
population survey for 2010.

Age group
16-24
25-54
55+

White non-Hispanic
Men
Women
453
424
878
715
990
734

Black non-Hispanic
Men
Women
403
404
656
615
740
614

Hispanic
Men Women
395
392
587
529
617
521

Notes: Wage data are in 2010 US dollars; in converting weekly wages to annual wages,
the assumption was that each year is consisted of 52 weeks.
Source: Weekly and Hourly Earnings from the Current Population Survey Bureau of
Labor Statistics. http://bls.gov/data/. Accessed 11/05/2012
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Table 4-22.

Mortality cost: Summary of results.
White non-Hispanic

Age
group
18-24
25-44
45-65
65+
All
Ages

%/$a
$

Black non-Hispanic

Hispanic

Male

Female

Both sexes

Male

Female

Both sexes

Male

Female

Both sexes

247.09 M

32.23 M

279.33 M

24.46 M

3.99 M

28.45 M

29.62 M

4.36 M

33.98 M

%

10.54

1.38

11.92

1.04

0.17

1.21

1.26

0.19

1.45

$

883.91 M

159.56 M

1.04 B

58.92 M

10.31 M

69.23 M

71.43 M

9.31 M

80.75 M

%

37.71

6.81

44.52

2.51

0.44

2.95

3.05

0.40

3.45

$

591.12 M

114.36 M

705.48 M

14.25 M

3,06 M

17.31 M

21.1 M

2.90 M

23.99 M

%

25.22

4.88

30.10

0.61

0.13

0.74

0.90

0.12

1.02

$

33.50 M

26.63 M

60.13 M

500,945

27,077

528,022

988,306

112,941

1.10 M

%

1.43

1.14

2.57

0.02

0.00

0.02

0.04

0.00

0.05

$

1.76 B

332.79 M

2.09 B

98.13 M

17.34 M

115.52 M

123.14 M

16.67 M

139.82 M

%

74.91

14.20

89.11

4.19

0.74

4.93

5.25

0.71

5.97

Total mortality cost in 2013 US dollar

2,343,749,010

a

$ represents the actual cost in 2013 US dollars, while % represents the share of cost in each cell from the total mortality cost,
in terms of percentage. For instance, White- non Hispanic males between the ages of 18 and 24, had $247.09 million mortality
cost, which accounts for 10.54% of the total mortality cost.
M = Million; B = Billion.

Table 4-23.

The societal cost of anxiety disorders for the U.S. adult population in 2010.
Indirect cost

Overall direct medical cost
$33,709,900,849 (69.12%)

Morbidity cost
$12,718,495,520 (26.08%)

Note: Costs are in 2013 US dollar values.
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Mortality cost
$2,343,749,010 (4.81%)

Societal cost
$48,772,145,379

CHAPTER 5.

DISCUSSION

Direct Medical Costs
General Notes
Our results showed that almost 9% of the ambulatory adult population of the U.S.
in 2009-2010 was diagnosed with anxiety disorder(s). This estimate is lower than the
18.1% estimate for the 12-month prevalence of any anxiety disorder, reported by the
National Comorbidity Survey Replication (NCS-R).9 This difference could be explained
by the fact that in MEPS, medical conditions are self-reported; while in the NCS-R, a
fully structured diagnostic interview was conducted to identify individuals with a
particular mental disorder. So, it is possible that some individuals with mild or moderate
anxiety disorder did not receive the diagnosis at the time of interview. Another possibility
is that some persons did not report their anxiety, simply because of the social stigma
attached to mental disorders. All these can lead to under-representation of anxiety
disorders in MEPS. Consistent with the NCS-R’s findings, this study also found that
prevalence of anxiety disorders is higher among women.
Unlike the previous researchers, who collected data from several different data
sources, only one database was used in the current study to estimate direct medical costs.
Using multiple data sources may lead to data inconsistency. To avoid this issue, we used
MEPS as the only data source for all analyses related to direct medical costs, since it
contains comprehensive information regarding the health care utilization and cost for
participants in the survey.
MEPS has been widely used by previous researchers for the estimation of diseaseattributable expense.60-64,66,84-86 In fact, when it comes to highly prevalent diseases, MEPS
is superior to administrative databases for cost estimation purposes in several ways. First
of all, it contains detailed information on demographic and clinical characteristics of
individuals, as well as their health care utilization and expenses. So, by controlling for all
factors that may affect healthcare expenditures in analysis, researchers can estimate costs
solely due to the condition of interest. Second of all, disease-attributable expenses can be
presented as point estimates, as well as percentage of total costs of the disease population.
This information, which cannot be gained using administrative data, provides a more
sensible picture of the economic burden of a disease;65 Finally, MEPS is the only
database which contains all required information to estimate direct medical expenditures
attributable to a disease. So instead of getting data from several different data sources,
which may lead to data inconsistency and later cast doubt on the reliability of results,
only one database is used to collect data on healthcare utilization and costs.
The confidence in the current findings is also derived from the adaptation of a
robust statistical analysis technique. In modeling healthcare cost data, an attempt was
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made to reduce bias in estimates by selecting statistical techniques that considered the
skewed nature of such data.
Overall Direct Medical Cost
Using estimates from this study, the annual incremental direct medical
expenditures attributable to anxiety disorders, for the U.S. ambulatory adult population, is
at $33.71 billion in 2013 US dollars. This figure, representing more than 69% of the
estimated societal cost, is obtained by multiplying the per-capita incremental cost of
anxiety ($1657.52) by the national estimated prevalence of anxiety disorders in MEPS
(20.34 million persons).
Previous estimates of direct medical costs of anxiety disorders, which were
obtained in the late 90’s, range from $28.73 billion to $98.26 billion in 2013 US
dollars.5,10 Even though our estimate falls within this range, it is not quite comparable
with the previous findings. The type of methodology used to estimate the costs has a
significant impact on results. DuPont et al.5 estimated the medical expenditures as the
product of volume of services and unit prices or charges, and Greenberg et al.10 estimates
were derived from a two-step multivariate regression approach, while we used the
incremental cost approach. In addition, their study population was not limited to the U.S.
ambulatory adult population, as ours was. Also, they did not include all diagnoses of
anxiety disorders in their analysis and considered different cost categories in estimating
cost of illness. For instance, DuPont et al.5 used charges instead of costs, did not include
costs due to PTSD, and almost 70% of their cost estimate ($19.9 billion) was due to costs
for institutionalized population, i.e. those who reside in nursing homes and specialty
mental health organizations. Greenburg et al.10 estimated cost of anxiety for individuals
aged 15 to 54. They found that more than half of the costs of these disorders ($53 billion)
were attributable to non-psychiatric direct medical expenditures. Interpreting this result,
Greenburg et al. explained that “estimation of this component was based on results from
a single staff–model HMO that may not be fully generalizable to the entire
population.”10(p. 431)
Cost by Category of Healthcare Services
With respect to categories of direct medical cost, inpatient visits (35.00%),
prescription medications (32.78%), and office-based medical provider visits (22.34%)
together accounted for almost 93% of the overall incremental costs associated with
anxiety disorders. Emergency room cost, representing almost 3% of overall medical
costs, was also slightly higher for sufferers of anxiety. These findings are consistent with
the known healthcare utilization pattern and treatment seeking behavior of individuals
with anxiety disorders. Marciniak, Lage, Landbloom, Dunayevich, and Bowman15
estimated the medical and productivity cost of anxiety disorders using data from a large
employer database. Their results showed that employees with anxiety disorders had
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higher inpatient hospital costs as well as higher prescription medications, medical
provider visits, and emergency care costs.
The high cost of office-based medical provider visits and prescription medications
can also be explained through the treatment seeking behavior of individuals with anxiety
disorders. Treatment options for anxiety disorders include pharmacotherapy,
psychotherapy, or combination of both. With the recent advances in psychotherapy
techniques and pharmacotherapy products, such as Cognitive-Behavioral Therapy (CBT)
and Selective Serotonin Reuptake Inhibitors (SSRIs) proven to be very effective in
treating anxiety disorders, treatment utilization for these conditions has significantly
increased throughout the time.87,88 As such, office-based medical provider visits and
prescription medications are expected to account for the majority of overall cost of illness
associated with anxiety disorders.
. To effectively reduce the cost of anxiety disorders, more attention needs to be
geared towards these three categories of care. For instance, further studies should
investigate the underlying reasons for high hospitalizations in patients with anxiety
disorders, and examine whether these hospitalizations are potentially preventable.
Cost for Different Sub-populations
Knowing which sub-population incurs higher costs, policymakers and clinicians
will be able to develop tailored disease management programs, by considering the
specific characteristics of the target sub-populations.
Our results showed that the following sub-populations accounted for the majority
of the overall direct medical costs associated with anxiety disorders in their category:
Females ($2137.98), individuals 65 years and older ($2426.40), White non-Hispanics
($1879.31), previously married individuals ($2305.23), those with high levels of
education (i.e. master/PhD) ($2463.31), middle-income earners ($2048.08), those who
reside in the Midwest ($2338.59), non-MSA residents ($2485.64), and dual eligible
($6455.84). The only sub-populations, in which having anxiety disorder(s) was not
associated with higher medical cost, were Hispanics, individuals with less than a high
school diploma/GED, the uninsured, and those who were covered only by Medicaid, or
other public insurances (such as Tricare).
Higher costs for females and White non-Hispanics can be explained through the
higher prevalence of anxiety disorders among these sub-populations.30 With respect to
insurance coverage, dual eligible followed by Medicare enrollees and private insurance
holders had the highest portion of medical costs. These plans usually offer more generous
benefits than Medicaid and other forms of public insurance. As such, it is expected for
their members to have higher utilization and cost for services such as psychotherapy
session, which are either not covered or limitedly covered by other plan types. The lifetime prevalence of anxiety disorders is the lowest for people 65 years and older; yet we
found that this group of individuals accounted for the majority of cost. This can be
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explained through the correlation between age and Medicare insurance coverage. Patients
with middle income, as well as those with high educational level had high anxiety-related
costs. This observation can be justified assuming that people with higher socioeconomic
status are more aware of the importance of treatment seeking for their diseases.
As it was mentioned above, anxiety disorders were not associated with an
increase in healthcare cost among Hispanics. Also, anxiety related costs for Black nonHispanics, even though statistically significant, were less than costs for White nonHispanics. One explanation for these observations could be the lower life-time prevalence
of anxiety disorders among Hispanics and Black non-Hispanics, in comparison with
White non-Hispanics.30 However, future research needs to be done to examine any
potential barrier in receiving the treatment for anxiety disorders among minorities.
To our knowledge, there is no study in the literature examining cost of anxiety
among different sub-populations. Murciniak et al.18 used MarketScan Databases to
examine how medical conditions and demographic characteristics affect the costs of
treating anxiety patients. The only demographic characteristics included in their analyses
were gender, age, and insurance coverage. Similar to our findings, they concluded that
females, older individuals, and those who have more comprehensive insurance coverage
incurred higher costs.18
We broke down anxiety costs for Blacks and Whites, by sex, gender and
geographic region. Our findings (i.e. considerable variation in incremental costs incurred
by different sub-populations), demonstrate why it is important to calculate values for subgroups; and highlight the need for future studies to figure out the underlying causes of
such variations. Of particular interest is the much larger costs for Black non-Hispanics in
the Northeast ($3899.40) and for Black non-Hispanic males aged 45 and older
($3932.22). These findings deserve additional study to determine the reasons for such
higher costs in theses sub-populations.
Indirect Costs
Based on the prevalence of self-reported anxiety disorders in MEPS and suicide
data from NVSS, the total annual indirect cost attributable to anxiety disorders was
estimated at $15.06 billion in 2013 US dollars ($12.72 for morbidity $2.34 for mortality
cost). This figure represents almost 31% of the estimated societal cost of anxiety
disorders.
Like direct medical cost, the estimated morbidity cost is also based on the
prevalence of self-reported anxiety disorders in MEPS. So, there is a possibility of underestimation of morbidity cost in this study (due to potential under-reporting of anxiety
disorders in MEPS).
There are only two studies that provided national estimates of indirect costs for
anxiety disorders. Greenberg et al.10 estimations of morbidity and mortality costs are
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$7.44 billion and $2.12 billion (in 2013 US dollars) respectively. Even though their
analysis technique for mortality cost is pretty similar to ours, their estimation of
morbidity cost is not quite comparable with our results, because:
x

They estimated productivity loss due to anxiety disorders only for the employed
individuals, while we considered both employed and unemployed individuals in
the analysis.

x

For employed individuals, they defined morbidity cost as the cost due to
absenteeism, plus reduced productivity while at work. The latter represented more
than 87% of their estimated morbidity cost. However, we did not include this
component (reduced productivity while at work) in our analysis.

x

To get the number of missed work days due to anxiety disorders, we used
regression analysis while they applied a 40% impairment rate to the total number
of work cutbacks.

DuPont et al.,5 also provided estimates of morbidity and mortality cost at $59.83
billion and $2.30 billion (in 2013 US dollars), respectively. In calculating the mortality
cost, they adopted the same methodology as ours, but their estimation of morbidity cost
was based on impairment rate, and thus is not comparable with our findings.
Societal Cost
The societal cost of anxiety disorders were estimated at 48.72 billion in 2013 US
dollars. Figure 5-1 shows the proportion of each cost component from the societal cost of
anxiety disorders for the ambulatory adult population of the United States.
This study used nationally representative databases along with a robust statistical
analysis technique to provide the most comprehensive and recent estimates of societal
cost of anxiety disorders among adults in the U.S. The current study demonstrates
conclusively that anxiety disorders, with the annual societal cost of $48.72 billion in 2013
US dollars, absorb a significant portion of US healthcare resources and should be
prioritized by policymakers and healthcare providers who aim to reduce downstream
costs of mental disorders.
Almost 70% of societal cost of anxiety disorders was due to direct medical costs.
We analyzed this category further by looking at the distribution of costs in different
health delivery settings, and amongst different sub-populations.
Our findings may also influence policy under the new Affordable Care Act
(ACA). The ACA, signed into law on March 2010, aims to: expand coverage for all
Americans, enhance the quality of care, and lower healthcare costs.89 In this regard,
economic evaluations, such as cost of illness studies, can serve as an important tool in
creating a healthcare system with lower costs and higher quality of care. Cost of illness
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Figure 5-1.

Percentage of each cost component from the societal cost.

studies are also useful in being able track healthcare costs over time to see if the increase
access to healthcare and the cost-reductions in the ACA are having an effect. Cost of
illness studies enable policymakers to identify medical conditions that absorb a
significant portion of the US healthcare budget. These costly medical conditions may be
investigated further to realize if resources are being distributed inefficiently, or if there is
a need to invest in new, cost-effective treatment options. All these will lead to prioritizing
scarce healthcare resources in a more efficient way, which eventually may lower the cost
of care. However, the ACA lacks a mechanism to directly use economic evaluations, to
reach these goals. As such, new healthcare policies are needed to support research that
will help prioritize allocation of scarce healthcare resources.
Limitations
This study has several limitations. Most importantly, our findings might have
underestimated the direct medical expenditures, as well as indirect cost aspect of
morbidity, attributable to anxiety disorders. As it was discussed earlier, individuals with
anxiety disorders were identified as those who reported being diagnosed with this
condition. So, prevalence of anxiety disorders might be under-reported in MEPS. As
such, our findings should be interpreted with caution. Results from this study, due to
potential under-representation of anxiety disorders in MEPS, should be interpreted as a
conservative estimate of the societal cost of these conditions in the ambulatory adult
population of the U.S. If we assume that health seeking behavior and healthcare
utilization of individuals with anxiety disorders, who didn’t report their condition, is not
systematically different from other individuals in the study population, then we can apply
the estimated per-person incremental medical cost ($1657.52) to the NCS-R’s estimate of
the 12-month prevalence of anxiety disorders (i.e. 18.1% of the adult population which is
equal to 42.13 million persons); and it gives us the total direct medical cost of anxiety
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disorders at $69.84 billion in 2013 US dollars. Similarly, assuming that productivity loss
of sufferers who reported their anxiety is consistent with the rest of the population, the
estimated morbidity cost would be $25.36 billion.
Second, some covariates such as history and severity of illness were not included
in the analysis of direct medical cost, due to unavailability of this information in MEPS.
Third, we studied the societal cost of anxiety disorders in the ambulatory adult population
of the U.S. A more comprehensive study including all age groups, as well as patients in
assisted living or nursing home facilities, in analysis would provide a more precise
estimate of the economic burden of these conditions. Fourth, since only the first three
digits of ICD-9 codes are shown in MEPS public use files, we couldn’t unbundle the
umbrella category of anxiety disorders and report costs by each diagnosis of these
conditions. Finally, in order to find the number of deaths due to anxiety disorders, we
applied a 10% rate to the total number of suicides. Even though we have adopted this rate
from previous relevant research, it may not be a very accurate estimate for anxietyinduced suicides. Unfortunately, the national number of suicides for each specific
diagnosis of mental illnesses is not still available.
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